{"id":"glimepiride","rwe":[{"pmid":"41900041","year":"2026","title":"Applications of Carbon Dots and Graphene Quantum Dots in Treatment of Diabetes.","finding":"","journal":"Molecules (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41888123","year":"2026","title":"Lactylation at lysine 145 fosters KAT8-TIP60 complex formation to promote p53 acetylation at lysine 120 and its pro-apoptotic function.","finding":"","journal":"Nature communications","studyType":"Clinical Study"},{"pmid":"41884285","year":"2026","title":"Recent Advances in Glimepiride Solubility Improvement: A Focus on Formulation Technologies - A Narrative Review.","finding":"","journal":"International journal of nanomedicine","studyType":"Clinical Study"},{"pmid":"41880439","year":"2026","title":"Cardioprotective effects of the ranolazine in myocardial infarction mediated by stimulation of the endogenous mediators involved in ischemic preconditioning.","finding":"","journal":"Acta cirurgica brasileira","studyType":"Clinical Study"},{"pmid":"41840294","year":"2026","title":"Floating-Mucoadhesive Gastro-Retentive Tablets for Enhanced Oral Delivery of Glimepiride: Formulation, Optimization, and Controlled Release.","finding":"","journal":"AAPS PharmSciTech","studyType":"Clinical Study"}],"_fda":{"id":"26cca05b-82f8-e191-e063-6394a90a56bd","set_id":"0003458f-352a-46fa-9d99-230daa76ae29","openfda":{"nui":["N0000175608","M0020795"],"unii":["6KY687524K"],"route":["ORAL"],"rxcui":["199245","199246","199247"],"spl_id":["26cca05b-82f8-e191-e063-6394a90a56bd"],"brand_name":["Glimepiride"],"spl_set_id":["0003458f-352a-46fa-9d99-230daa76ae29"],"package_ndc":["68084-788-95","68084-788-25","68084-326-11","68084-326-01","68084-327-11","68084-327-01"],"product_ndc":["68084-326","68084-788","68084-327"],"generic_name":["GLIMEPIRIDE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_cs":["Sulfonylurea Compounds [CS]"],"substance_name":["GLIMEPIRIDE"],"pharm_class_epc":["Sulfonylurea [EPC]"],"manufacturer_name":["American Health Packaging"],"application_number":["ANDA077091"],"original_packager_product_ndc":["55111-320","55111-321","55111-322"]},"version":"11","pregnancy":["8.1 Pregnancy Risk Summary Available data from a small number of published studies and postmarketing experience with glimepiride use in pregnancy over decades have not identified any drug associated risks for major birth defects, miscarriage, or adverse maternal outcomes. However, sulfonylureas (including glimepiride) cross the placenta and have been associated with neonatal adverse reactions such as hypoglycemia. Therefore, glimepiride tablets should be discontinued at least two weeks before expected delivery (see Clinical Considerations). Poorly controlled diabetes in pregnancy is also associated with risks to the mother and fetus (see Clinical Considerations). In animal studies (see Data), there were no effects on embryo-fetal development following administration of glimepiride to pregnant rats and rabbits at oral doses approximately 4,000 times and 60 times the maximum human dose based on body surface area, respectively. However, fetotoxicity was observed in rats and rabbits at doses 50 times and 0.1 times the maximum human dose, respectively. The estimated background risk of major birth defects is 6% to 10% in women with pregestational diabetes with a HbA 1c >7% and has been reported to be as high as 20% to 25% in women with a HbA 1c >10%. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo-fetal risk Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, preeclampsia, spontaneous abortions, preterm delivery, and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, still birth, and macrosomia-related morbidity. Fetal/neonatal adverse reactions Neonates of women with gestational diabetes who are treated with sulfonylureas during pregnancy may be at increased risk for neonatal intensive care admission and may develop respiratory distress, hypoglycemia, birth injury, and be large for gestational age. Prolonged severe hypoglycemia, lasting 4 to 10 days, has been reported in neonates born to mothers receiving a sulfonylurea at the time of delivery and has been reported with the use of agents with a prolonged half-life. Observe newborns for symptoms of hypoglycemia and respiratory distress and manage accordingly. Dose adjustments during pregnancy and the postpartum period Due to reports of prolonged severe hypoglycemia in neonates born to mothers receiving a sulfonylurea at the time of delivery, glimepiride tablets should be discontinued at least two weeks before expected delivery (see Fetal/Neonatal Adverse Reactions). Data Animal data In animal studies, there was no increase in congenital anomalies, but an increase in fetal deaths occurred in rats and rabbits at glimepiride doses 50 times (rats) and 0.1 times (rabbits) the maximum recommended human dose (based on body surface area). This fetotoxicity was observed only at doses inducing maternal hypoglycemia and is believed to be directly related to the pharmacologic (hypoglycemic) action of glimepiride, as has been similarly noted with other sulfonylureas."],"overdosage":["10 OVERDOSAGE An overdosage of glimepiride tablets, as with other sulfonylureas, can produce severe hypoglycemia. Mild episodes of hypoglycemia can be treated with oral glucose. Severe hypoglycemic reactions constitute medical emergencies requiring immediate treatment. Severe hypoglycemia with coma, seizure, or neurological impairment can be treated with glucagon or intravenous glucose. Continued observation and additional carbohydrate intake may be necessary because hypoglycemia may recur after apparent clinical recovery [see Warnings and Precautions (5.1) ]."],"description":["11 DESCRIPTION Glimepiride tablets USP, are an oral sulfonylurea that contains the active ingredient glimepiride USP. Chemically, glimepiride USP is identified as 1-[[p-[2-(3-ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido) ethyl]phenyl]sulfonyl]-3-(trans-4-methylcyclohexyl)urea (C 24 H 34 N 4 O 5 S) with a molecular weight of 490.62. Glimepiride USP is a white to almost white powder, soluble in dimethyl formamide, sparingly soluble in methylene chloride, practically insoluble in water. The structural formula is: Glimepiride tablets meets USP drug release test 2. Glimepiride tablets USP, contain the active ingredient glimepiride USP and the following inactive ingredients: lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone and sodium starch glycolate. In addition, glimepiride 1 mg tablets contain ferric oxide red, glimepiride 2 mg tablets contain lake blend green (contains D&C yellow # 10 aluminium lake and FD&C blue #1/ brilliant blue FCF aluminium lake) and glimepiride 4 mg tablets contain lake blend blue (contains D&C yellow # 10 aluminium lake and FD&C blue # 1/ brilliant blue FCF aluminium lake). Structural Formula"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Glimepiride tablets USP, are available in the following strengths and package sizes: Glimepiride tablets USP, 1 mg are peach, oval, flat beveled edged, uncoated tablets debossed “RDY” on one side and “320” separating “3” and “20” with bisect line scoring on the other side and are supplied in: Unit dose packages of 30 (5 x 6) NDC 68084-788-25 Glimepiride tablets USP, 2 mg are green, oval, flat beveled edged, uncoated tablets debossed “RDY” on one side and “321” separating “3” and “21” with bisect line scoring on the other side and are supplied in: Unit dose packages of 100 (10 x 10) NDC 68084-326-01 Glimepiride tablets USP, 4 mg are blue, oval, flat beveled edged, uncoated tablets debossed “RDY” on one side and “322” separating “3” and “22” with bisect line scoring on the other side and are supplied in: Unit dose packages of 100 (10 x 10) NDC 68084-327-01 Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. FOR YOUR PROTECTION: Do not use if blister is torn or broken."],"geriatric_use":["8.5 Geriatric Use In clinical trials of glimepiride, 1053 of 3491 patients (30%) were >65 years of age. No overall differences in safety or effectiveness were observed between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out. There were no significant differences in glimepiride pharmacokinetics between patients with type 2 diabetes ≤65 years (n=49) and those >65 years (n=42) [see Clinical Pharmacology (12.3) ]. Glimepiride is substantially excreted by the kidney. Elderly patients are more likely to have renal impairment. In addition, hypoglycemia may be difficult to recognize in the elderly [see Dosage and Administration (2.1) and Warnings and Precautions (5.1) ]. Use caution when initiating glimepiride and increasing the dose of glimepiride tablets in this patient population."],"pediatric_use":["8.4 Pediatric Use The pharmacokinetics, efficacy and safety of glimepiride have been evaluated in pediatric patients with type 2 diabetes as described below. Glimepiride tablets are not recommended in pediatric patients because of its adverse effects on body weight and hypoglycemia. The pharmacokinetics of a 1 mg single dose of glimepiride was evaluated in 30 patients with type 2 diabetes (male = 7; female = 23) between ages 10 and 17 years. The mean (± SD) AUC (0-last) (339±203 ng•hr/mL), C max (102±48 ng/mL) and t 1/2 (3.1±1.7 hours) for glimepiride were comparable to historical data from adults (AUC (0-last) 315±96 ng•hr/mL, C max 103±34 ng/mL and t 1/2 5.3±4.1 hours). The safety and efficacy of glimepiride in pediatric patients was evaluated in a single-blind, 24-week trial that randomized 272 patients (8 to 17 years of age) with type 2 diabetes to glimepiride (n=135) or metformin (n=137). Both treatment-naïve patients (those treated with only diet and exercise for at least 2 weeks prior to randomization) and previously treated patients (those previously treated or currently treated with other oral antidiabetic medications for at least 3 months) were eligible to participate. Patients who were receiving oral antidiabetic agents at the time of study entry discontinued these medications before randomization without a washout period. Glimepiride was initiated at 1 mg, and then titrated up to 2, 4 or 8 mg (mean last dose 4 mg) through Week 12, targeting a self-monitored fasting fingerstick blood glucose < 126 mg/dL. Metformin was initiated at 500 mg twice daily and titrated at Week 12 up to 1000 mg twice daily (mean last dose 1365 mg). After 24 weeks, the overall mean treatment difference in HbA 1c between glimepiride and metformin was 0.2%, favoring metformin (95% confidence interval -0.3% to +0.6%). Based on these results, the trial did not meet its primary objective of showing a similar reduction in HbA 1c with glimepiride compared to metformin. Table 2. Change from Baseline in HbA 1C and Body Weight in Pediatric Patients Taking Glimepiride or Metformin Metformin Glimepiride Treatment-Naïve Patients Intent-to-treat population using last-observation-carried-forward for missing data (Glimepiride, n=127; metformin, n=126) N=69 N=72 HbA 1C (%) Baseline (mean) 8.2 8.3 Change from baseline (adjusted LS mean) adjusted for baseline HbA1c and Tanner Stage -1.2 -1 Adjusted Treatment Difference Difference is glimepiride – metformin with positive differences favoring metformin (95% CI) 0.2 (-0.3; 0.6) Previously Treated Patients N=57 N=55 HbA 1C (%) Baseline (mean) 9 8.7 Change from baseline (adjusted LS mean) -0.2 0.2 Adjusted Treatment Difference (95% CI) 0.4 (-0.4; 1.2) Body Weight (kg) N=126 N=129 Baseline (mean) 67.3 66.5 Change from baseline (adjusted LS mean) 0.7 2 Adjusted Treatment Difference (95% CI) 1.3 (0.3; 2.3) The profile of adverse reactions in pediatric patients treated with glimepiride was similar to that observed in adults [see Adverse Reactions (6) ]. Hypoglycemic events documented by blood glucose values <36 mg/dL were observed in 4% of pediatric patients treated with glimepiride and in 1% of pediatric patients treated with metformin. One patient in each treatment group experienced a severe hypoglycemic episode (severity was determined by the investigator based on observed signs and symptoms)."],"effective_time":"20241113","clinical_studies":["14 CLINICAL STUDIES 14.1 Monotherapy A total of 304 patients with type 2 diabetes already treated with sulfonylurea therapy participated in a 14-week, multicenter, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of glimepiride monotherapy. Patients discontinued their sulfonylurea therapy then entered a 3-week placebo washout period followed by randomization into 1 of 4 treatment groups: placebo (n=74), glimepiride tablets 1 mg (n=78), glimepiride tablets 4 mg (n=76) and glimepiride tablets 8 mg (n=76). All patients randomized to glimepiride tablets started 1 mg daily. Patients randomized to glimepiride tablets 4 mg or 8 mg had blinded, forced titration of the glimepiride tablets dose at weekly intervals, first to 4 mg and then to 8 mg, as long as the dose was tolerated, until the randomized dose was reached. Patients randomized to the 4 mg dose reached the assigned dose at Week 2. Patients randomized to the 8 mg dose reached the assigned dose at Week 3. Once the randomized dose level was reached, patients were to be maintained at that dose until Week 14. Approximately 66% of the placebo-treated patients completed the trial compared to 81% of patients treated with glimepiride 1 mg and 92% of patients treated with glimepiride 4 mg or 8 mg. Compared to placebo, treatment with glimepiride tablets 1 mg, 4 mg and 8 mg daily provided statistically significant improvements in HbA 1C compared to placebo (Table 3). Table 3. 14-week Monotherapy Trial Comparing Glimepiride to Placebo in Patients Previously Treated With Sulfonylurea Therapy Intent-to-treat population using last observation on study Placebo (N=74) Glimepiride 1 mg (N=78) 4 mg (N=76) 8 mg (N=76) HbA 1C (%) n=59 n=65 n=65 n=68 Baseline (mean) 8 7.9 7.9 8 Change from Baseline (adjusted mean Least squares mean adjusted for baseline value ) 1.5 0.3 -0.3 -0.4 Difference from Placebo (adjusted mean ) 95% confidence interval -1.2 p<0.001 (-1.5, -0.8) -1.8 (-2.1, -1.4) -1.8 (-2.2, -1.5) Mean Baseline Weight (kg) n=67 n=76 n=75 n=73 Baseline (mean) 85.7 84.3 86.1 85.5 Change from Baseline (adjusted mean ) -2.3 -0.2 0.5 1 Difference from Placebo (adjusted mean ) 95% confidence interval 2 (1.4, 2.7) 2.8 (2.1, 3.5) 3.2 (2.5, 4) A total of 249 patients who were treatment-naïve or who had received limited treatment with antidiabetic therapy in the past were randomized to receive 22 weeks of treatment with either glimepiride (n=123) or placebo (n=126) in a multicenter, randomized, double-blind, placebo-controlled, dose-titration trial. The starting dose of glimepiride tablets was 1 mg daily and was titrated upward or downward at 2-week intervals to a goal FPG of 90 to 150 mg/dL. Blood glucose levels for both FPG and PPG were analyzed in the laboratory. Following 10 weeks of dose adjustment, patients were maintained at their optimal dose (1, 2, 3, 4, 6 or 8 mg) for the remaining 12 weeks of the trial. Treatment with glimepiride provided statistically significant improvements in HbA 1C and FPG compared to placebo (Table 4). Table 4. 22-Week Monotherapy Trial Comparing Glimepiride to Placebo in Patients Who Were Treatment-Naïve or Who Had No Recent Treatment with Antidiabetic Therapy Intent to treat population using last observation on study Placebo (N=126) Glimepiride (N=123) HbA 1C (%) n=97 n=106 Baseline (mean) 9.1 9.3 Change from Baseline (adjusted mean Least squares mean adjusted for baseline value ) -1.1 p<0.0001 -2.2 Difference from Placebo (adjusted mean ) 95% confidence interval -1.1 (-1.5, -0.8) Body Weight (kg) n=122 n=119 Baseline (mean) 86.5 87.1 Change from Baseline (adjusted mean ) -0.9 1.8 Difference from Placebo (adjusted mean ) 95% confidence interval 2.7 (1.9, 3.6)"],"pharmacodynamics":["12.2 Pharmacodynamics In healthy subjects, the time to reach maximal effect (minimum blood glucose concentrations) was approximately 2 to 3 hours after single oral doses of glimepiride tablets. The effects of glimepiride on HbA 1c , fasting plasma glucose, and postprandial glucose have been assessed in clinical trials [see Clinical Studies (14) ]."],"pharmacokinetics":["12.3 Pharmacokinetics Absorption Studies with single oral doses of glimepiride in healthy subjects and with multiple oral doses in patients with type 2 diabetes showed peak drug concentrations (C max ) 2 to 3 hours postdose. When glimepiride was given with meals, the mean C max and AUC (area under the curve) were decreased by 8% and 9%, respectively. Glimepiride does not accumulate in serum following multiple dosing. The pharmacokinetics of glimepiride does not differ between healthy subjects and patients with type 2 diabetes. Clearance of glimepiride after oral administration does not change over the 1 mg to 8 mg dose range, indicating linear pharmacokinetics. In healthy subjects, the intraindividual and interindividual variabilities of glimepiride pharmacokinetic parameters were 15% to 23% and 24% to 29%, respectively. Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min. Protein binding was greater than 99.5%. Metabolism Glimepiride is completely metabolized by oxidative biotransformation after either an intravenous or oral dose. The major metabolites are the cyclohexyl hydroxy methyl derivative (M1) and the carboxyl derivative (M2). Cytochrome P450 2C9 is involved in the biotransformation of glimepiride to M1. M1 is further metabolized to M2 by one or several cytosolic enzymes. M2 is inactive. In animals, M1 possesses about one-third of the pharmacological activity of glimepiride, but it is unclear whether M1 results in clinically meaningful effects on blood glucose in humans. Excretion When 14 C-glimepiride was given orally to 3 healthy male subjects, approximately 60% of the total radioactivity was recovered in the urine in 7 days. M1 and M2 accounted for 80% to 90% of the radioactivity recovered in the urine. The ratio of M1 to M2 in the urine was approximately 3:2 in two subjects and 4:1 in one subject. Approximately 40% of the total radioactivity was recovered in feces. M1 and M2 accounted for about 70% (ratio of M1 to M2 was 1:3) of the radioactivity recovered in feces. No parent drug was recovered from urine or feces. After intravenous dosing in patients, no significant biliary excretion of glimepiride or its M1 metabolite was observed. Specific Populations Geriatric Patients A comparison of glimepiride pharmacokinetics in patients with type 2 diabetes ≤65 years and those >65 years was evaluated in a multiple-dose study using glimepiride tablets 6 mg daily. There were no significant differences in glimepiride pharmacokinetics between the two age groups. The mean AUC at steady state for the older patients was approximately 13% lower than that for the younger patients; the mean weight-adjusted clearance for the older patients was approximately 11% higher than that for the younger patients. Gender There were no differences between males and females in the pharmacokinetics of glimepiride when adjustment was made for differences in body weight. Race No studies have been conducted to assess the effects of race on glimepiride pharmacokinetics but in placebo-controlled trials of glimepiride in patients with type 2 diabetes, the reduction in HbA 1C was comparable in Caucasians (n = 536), blacks (n = 63), and Hispanics (n = 63). Renal Impairment In a single-dose, open-label study glimepiride tablets 3 mg was administered to patients with mild, moderate and severe renal impairment as estimated by creatinine clearance (CLcr): Group I consisted of 5 patients with mild renal impairment (CLcr > 50 mL/min), Group II consisted of 3 patients with moderate renal impairment (CLcr = 20 to 50 mL/min) and Group III consisted of 7 patients with severe renal impairment (CLcr < 20 mL/min). Although, glimepiride serum concentrations decreased with decreasing renal function, Group III had a 2.3-fold higher mean AUC for M1 and an 8.6-fold higher mean AUC for M2 compared to corresponding mean AUCs in Group I. The apparent terminal half-life (T 1/2 ) for glimepiride did not change, while the half-lives for M1 and M2 increased as renal function decreased. Mean urinary excretion of M1 plus M2 as a percentage of dose decreased from 44.4% for Group I to 21.9% for Group II and 9.3% for Group III. Hepatic Impairment It is unknown whether there is an effect of hepatic impairment on glimepiride pharmacokinetics because the pharmacokinetics of glimepiride has not been adequately evaluated in patients with hepatic impairment. Obese Patients The pharmacokinetics of glimepiride and its metabolites were measured in a single-dose study involving 28 patients with type 2 diabetes who either had normal body weight or were morbidly obese. While the t max , clearance, and volume of distribution of glimepiride in the morbidly obese patients were similar to those in the normal weight group, the morbidly obese had lower C max and AUC than those of normal body weight. The mean C max , AUC 0-24 , AUC 0-∞ values of glimepiride in normal vs. morbidly obese patients were 547 ± 218 ng/mL vs. 410 ± 124 ng/mL, 3210 ± 1030 hours·ng/mL vs. 2820 ± 1110 hours·ng/mL and 4000 ± 1320 hours·ng/mL vs. 3280 ± 1360 hours·ng/mL, respectively. Drug Interactions Aspirin In a randomized, double-blind, two-period, crossover study, healthy subjects were given either placebo or aspirin 1 gram three times daily for a total treatment period of 5 days. On Day 4 of each study period, a single 1 mg dose of glimepiride tablets was administered. The glimepiride tablets doses were separated by a 14-day washout period. Coadministration of aspirin and glimepiride resulted in a 34% decrease in the mean glimepiride AUC and a 4% decrease in the mean glimepiride C max . Colesevelam Concomitant administration of colesevelam and glimepiride resulted in reductions in glimepiride AUC 0-∞ and C max of 18% and 8%, respectively. When glimepiride was administered 4 hours prior to colesevelam, there was no significant change in glimepiride AUC 0-∞ or C max , -6% and 3%, respectively [see Dosage and Administration (2.1) and Drug Interactions (7.4) ]. Cimetidine and Ranitidine In a randomized, open-label, 3-way crossover study, healthy subjects received either a single 4 mg dose of glimepiride tablets alone, glimepiride with ranitidine (150 mg twice daily for 4 days; glimepiride was administered on Day 3), or glimepiride with cimetidine (800 mg daily for 4 days; glimepiride was administered on Day 3). Co-administration of cimetidine or ranitidine with a single 4 mg oral dose of glimepiride tablets did not significantly alter the absorption and disposition of glimepiride. Propranolol In a randomized, double-blind, two-period, crossover study, healthy subjects were given either placebo or propranolol 40 mg three times daily for a total treatment period of 5 days. On Day 4 of each study period, a single 2 mg dose of glimepiride tablets was administered. The glimepiride tablets doses were separated by a 14-day washout period. Concomitant administration of propranolol and glimepiride significantly increased glimepiride C max , AUC, and T 1/2 by 23%, 22%, and 15%, respectively, and decreased glimepiride CL/f by 18%. The recovery of M1 and M2 from urine was not changed. Warfarin In an open-label, two-way, crossover study, healthy subjects received 4 mg of glimepiride tablets daily for 10 days. Single 25 mg doses of warfarin were administered 6 days before starting glimepiride and on Day 4 of glimepiride administration. The concomitant administration of glimepiride did not alter the pharmacokinetics of R- and S-warfarin enantiomers. No changes were observed in warfarin plasma protein binding. Glimepiride resulted in a statistically significant decrease in the pharmacodynamic response to warfarin. The reductions in mean area under the prothrombin time (PT) curve and maximum PT values during glimepiride treatment were 3.3% and 9.9%, respectively, and are unlikely to be clinically relevant."],"adverse_reactions":["6 ADVERSE REACTIONS The following serious adverse reactions are discussed in more detail below and elsewhere in the labeling: Hypoglycemia [see Warnings and Precautions (5.1) ] Hemolytic anemia [see Warnings and Precautions (5.3) ] In clinical trials, the most common adverse reactions with glimepiride were hypoglycemia, dizziness, asthenia, headache, and nausea. Common adverse reactions in clinical trials (≥5% and more common than with placebo) include hypoglycemia, headache, nausea, and dizziness ( 6.1 ). To report SUSPECTED ADVERSE REACTIONS, contact Dr. Reddy’s Laboratories, Inc. at 1-888-375-3784 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Approximately 2,800 patients with type 2 diabetes have been treated with glimepiride in the controlled clinical trials. In these trials, approximately 1,700 patients were treated with glimepiride for at least 1 year. Table 1 summarizes adverse events, other than hypoglycemia, that were reported in 11 pooled placebo-controlled trials, whether or not considered to be possibly or probably related to study medication. Treatment duration ranged from 13 weeks to 12 months. Terms that are reported represent those that occurred at an incidence of ≥5% among glimepiride-treated patients and more commonly than in patients who received placebo. Table 1. Eleven Pooled Placebo-Controlled Trials ranging from 13 weeks to 12 months: Adverse Events (excluding hypoglycemia) Occurring in ≥5% of glimepiride-treated Patients and at a Greater Incidence than with Placebo Glimepiride doses ranged from 1 to 16 mg administered daily Glimepiride N=745 % Placebo N=294 % Headache 8.2 7.8 Accidental Injury Insufficient information to determine whether any of the accidental injury events were associated with hypoglycemia 5.8 3.4 Flu Syndrome 5.4 4.4 Nausea 5 3.4 Dizziness 5 2.4 Hypoglycemia In a randomized, double-blind, placebo-controlled monotherapy trial of 14 weeks duration, patients already on sulfonylurea therapy underwent a 3-week washout period then were randomized to glimepiride tablets 1 mg, 4 mg, 8 mg or placebo. Patients randomized to glimepiride tablets 4 mg or 8 mg underwent forced-titration from an initial dose of 1 mg to these final doses, as tolerated [see Clinical Studies (14.1) ]. The overall incidence of possible hypoglycemia (defined by the presence of at least one symptom that the investigator believed might be related to hypoglycemia; a concurrent glucose measurement was not required) was 4% for glimepiride tablets 1 mg, 17% for glimepiride tablets 4 mg, 16% for glimepiride tablets 8 mg and 0% for placebo. All of these events were self-treated. In a randomized, double-blind, placebo-controlled monotherapy trial of 22 weeks duration, patients received a starting dose of either 1 mg glimepiride tablets or placebo daily. The dose of glimepiride tablets was titrated to a target fasting plasma glucose of 90 to 150 mg/dL. Final daily doses of glimepiride tablets were 1, 2, 3, 4, 6 or 8 mg [see Clinical Studies (14.1) ]. The overall incidence of possible hypoglycemia (as defined above for the 14-week trial) for glimepiride vs. placebo was 19.7% vs. 3.2%. All of these events were self-treated. Weight gain Glimepiride, like all sulfonylureas, can cause weight gain [see Clinical Studies (14.1) ]. Allergic Reactions In clinical trials, allergic reactions, such as pruritus, erythema, urticaria, and morbilliform or maculopapular eruptions, occurred in less than 1% of glimepiride-treated patients. These may resolve despite continued treatment with glimepiride. There are postmarketing reports of more serious allergic reactions (e.g., dyspnea, hypotension, shock) [see Warnings and Precautions (5.2) ]. Laboratory Tests Elevated Serum Alanine Aminotransferase (ALT) In 11 pooled placebo-controlled trials of glimepiride, 1.9% of glimepiride-treated patients and 0.8% of placebo-treated patients developed serum ALT greater than 2 times the upper limit of the reference range. 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of glimepiride. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Serious hypersensitivity reactions, including anaphylaxis, angioedema, and Stevens-Johnson Syndrome [see Warnings and Precautions (5.2) ] Hemolytic anemia in patients with and without G6PD deficiency [see Warnings and Precautions (5.3) ] Impairment of liver function (e.g., with cholestasis and jaundice), as well as hepatitis, which may progress to liver failure. Porphyria cutanea tarda, photosensitivity reactions and allergic vasculitis Leukopenia, agranulocytosis, aplastic anemia, and pancytopenia Thrombocytopenia (including severe cases with platelet count less than 10,000/μL) and thrombocytopenic purpura Hepatic porphyria reactions and disulfiram-like reactions Hyponatremia and syndrome of inappropriate antidiuretic hormone secretion (SIADH), most often in patients who are on other medications or who have medical conditions known to cause hyponatremia or increase release of antidiuretic hormone Dysgeusia Alopecia"],"contraindications":["4 CONTRAINDICATIONS Glimepiride tablets are contraindicated in patients with a history of a hypersensitivity reaction to: Glimepiride or any of the product’s ingredients [see Warnings and Precautions (5.2) ]. Sulfonamide derivatives: Patients who have developed an allergic reaction to sulfonamide derivatives may develop an allergic reaction to glimepiride. Do not use glimepiride in patients who have a history of an allergic reaction to sulfonamide derivatives. Hypersensitivity to glimepiride or any of the product’s ingredients ( 4 ) Hypersensitivity to sulfonamide derivatives ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS Certain medications may affect glucose metabolism, requiring glimepiride tablets dose adjustment and close monitoring of blood glucose ( 7.1 ). Miconazole: Severe hypoglycemia can occur when glimepiride and oral miconazole are used concomitantly. ( 7.2 ). Cytochrome P450 2C9 interactions: Inhibitors and inducers of cytochrome P450 2C9 may affect glycemic control by altering glimepiride plasma concentrations ( 7.3 ). Colesevelam: Coadministration may reduce glimepiride absorption. Glimepiride should be administered at least 4 hours prior to colesevelam ( 2.1 , 7.4 ). 7.1 Drugs Affecting Glucose Metabolism A number of medications affect glucose metabolism and may require glimepiride tablets dose adjustment and particularly close monitoring for hypoglycemia or worsening glycemic control. The following are examples of medications that may increase the glucose-lowering effect of sulfonylureas including glimepiride, increasing the susceptibility to and/or intensity of hypoglycemia: oral anti-diabetic medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibitors, H 2 receptor antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are highly protein-bound, such as fluoxetine, nonsteroidal anti-inflammatory drugs, salicylates, sulfonamides, chloramphenicol, coumarins, probenecid and monoamine oxidase inhibitors. When these medications are administered to a patient receiving glimepiride, monitor the patient closely for hypoglycemia. When these medications are withdrawn from a patient receiving glimepiride, monitor the patient closely for worsening glycemic control. The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid. When these medications are administered to a patient receiving glimepiride, monitor the patient closely for worsening glycemic control. When these medications are withdrawn from a patient receiving glimepiride, monitor the patient closely for hypoglycemia. Beta-blockers, clonidine, and reserpine may lead to either potentiation or weakening of glimepiride’s glucose-lowering effect. Both acute and chronic alcohol intake may potentiate or weaken the glucose-lowering action of glimepiride in an unpredictable fashion. The signs of hypoglycemia may be reduced or absent in patients taking sympatholytic drugs such as beta-blockers, clonidine, guanethidine, and reserpine. 7.2 Miconazole A potential interaction between oral miconazole and sulfonylureas leading to severe hypoglycemia has been reported. Whether this interaction also occurs with other dosage forms of miconazole is not known. 7.3 Cytochrome P450 2C9 Interactions There may be an interaction between glimepiride and inhibitors (e.g., fluconazole) and inducers (e.g., rifampin) of cytochrome P450 2C9. Fluconazole may inhibit the metabolism of glimepiride, causing increased plasma concentrations of glimepiride which may lead to hypoglycemia. Rifampin may induce the metabolism of glimepiride, causing decreased plasma concentrations of glimepiride which may lead to worsening glycemic control. 7.4 Concomitant Administration of Colesevelam Colesevelam can reduce the maximum plasma concentration and total exposure of glimepiride when the two are coadministered. However, absorption is not reduced when glimepiride is administered 4 hours prior to colesevelam. Therefore, glimepiride should be administered at least 4 hours prior to colesevelam."],"mechanism_of_action":["12.1 Mechanism of Action Glimepiride primarily lowers blood glucose by stimulating the release of insulin from pancreatic beta cells. Sulfonylureas bind to the sulfonylurea receptor in the pancreatic beta-cell plasma membrane, leading to closure of the ATP-sensitive potassium channel, thereby stimulating the release of insulin."],"pediatric_use_table":["
Table 2. Change from Baseline in HbA 1C and Body Weight in Pediatric Patients Taking Glimepiride or Metformin
MetforminGlimepiride
Treatment-Naïve PatientsIntent-to-treat population using last-observation-carried-forward for missing data (Glimepiride, n=127; metformin, n=126)N=69N=72
HbA 1C (%)
Baseline (mean)8.28.3
Change from baseline (adjusted LS mean) adjusted for baseline HbA1c and Tanner Stage -1.2-1
Adjusted Treatment Difference Difference is glimepiride – metformin with positive differences favoring metformin (95% CI) 0.2 (-0.3; 0.6)
Previously Treated PatientsN=57N=55
HbA 1C (%)
Baseline (mean)98.7
Change from baseline (adjusted LS mean) -0.20.2
Adjusted Treatment Difference (95% CI) 0.4 (-0.4; 1.2)
Body Weight (kg)N=126N=129
Baseline (mean)67.366.5
Change from baseline (adjusted LS mean) 0.72
Adjusted Treatment Difference (95% CI) 1.3 (0.3; 2.3)
"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Glimepiride primarily lowers blood glucose by stimulating the release of insulin from pancreatic beta cells. Sulfonylureas bind to the sulfonylurea receptor in the pancreatic beta-cell plasma membrane, leading to closure of the ATP-sensitive potassium channel, thereby stimulating the release of insulin. 12.2 Pharmacodynamics In healthy subjects, the time to reach maximal effect (minimum blood glucose concentrations) was approximately 2 to 3 hours after single oral doses of glimepiride tablets. The effects of glimepiride on HbA 1c , fasting plasma glucose, and postprandial glucose have been assessed in clinical trials [see Clinical Studies (14) ]. 12.3 Pharmacokinetics Absorption Studies with single oral doses of glimepiride in healthy subjects and with multiple oral doses in patients with type 2 diabetes showed peak drug concentrations (C max ) 2 to 3 hours postdose. When glimepiride was given with meals, the mean C max and AUC (area under the curve) were decreased by 8% and 9%, respectively. Glimepiride does not accumulate in serum following multiple dosing. The pharmacokinetics of glimepiride does not differ between healthy subjects and patients with type 2 diabetes. Clearance of glimepiride after oral administration does not change over the 1 mg to 8 mg dose range, indicating linear pharmacokinetics. In healthy subjects, the intraindividual and interindividual variabilities of glimepiride pharmacokinetic parameters were 15% to 23% and 24% to 29%, respectively. Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min. Protein binding was greater than 99.5%. Metabolism Glimepiride is completely metabolized by oxidative biotransformation after either an intravenous or oral dose. The major metabolites are the cyclohexyl hydroxy methyl derivative (M1) and the carboxyl derivative (M2). Cytochrome P450 2C9 is involved in the biotransformation of glimepiride to M1. M1 is further metabolized to M2 by one or several cytosolic enzymes. M2 is inactive. In animals, M1 possesses about one-third of the pharmacological activity of glimepiride, but it is unclear whether M1 results in clinically meaningful effects on blood glucose in humans. Excretion When 14 C-glimepiride was given orally to 3 healthy male subjects, approximately 60% of the total radioactivity was recovered in the urine in 7 days. M1 and M2 accounted for 80% to 90% of the radioactivity recovered in the urine. The ratio of M1 to M2 in the urine was approximately 3:2 in two subjects and 4:1 in one subject. Approximately 40% of the total radioactivity was recovered in feces. M1 and M2 accounted for about 70% (ratio of M1 to M2 was 1:3) of the radioactivity recovered in feces. No parent drug was recovered from urine or feces. After intravenous dosing in patients, no significant biliary excretion of glimepiride or its M1 metabolite was observed. Specific Populations Geriatric Patients A comparison of glimepiride pharmacokinetics in patients with type 2 diabetes ≤65 years and those >65 years was evaluated in a multiple-dose study using glimepiride tablets 6 mg daily. There were no significant differences in glimepiride pharmacokinetics between the two age groups. The mean AUC at steady state for the older patients was approximately 13% lower than that for the younger patients; the mean weight-adjusted clearance for the older patients was approximately 11% higher than that for the younger patients. Gender There were no differences between males and females in the pharmacokinetics of glimepiride when adjustment was made for differences in body weight. Race No studies have been conducted to assess the effects of race on glimepiride pharmacokinetics but in placebo-controlled trials of glimepiride in patients with type 2 diabetes, the reduction in HbA 1C was comparable in Caucasians (n = 536), blacks (n = 63), and Hispanics (n = 63). Renal Impairment In a single-dose, open-label study glimepiride tablets 3 mg was administered to patients with mild, moderate and severe renal impairment as estimated by creatinine clearance (CLcr): Group I consisted of 5 patients with mild renal impairment (CLcr > 50 mL/min), Group II consisted of 3 patients with moderate renal impairment (CLcr = 20 to 50 mL/min) and Group III consisted of 7 patients with severe renal impairment (CLcr < 20 mL/min). Although, glimepiride serum concentrations decreased with decreasing renal function, Group III had a 2.3-fold higher mean AUC for M1 and an 8.6-fold higher mean AUC for M2 compared to corresponding mean AUCs in Group I. The apparent terminal half-life (T 1/2 ) for glimepiride did not change, while the half-lives for M1 and M2 increased as renal function decreased. Mean urinary excretion of M1 plus M2 as a percentage of dose decreased from 44.4% for Group I to 21.9% for Group II and 9.3% for Group III. Hepatic Impairment It is unknown whether there is an effect of hepatic impairment on glimepiride pharmacokinetics because the pharmacokinetics of glimepiride has not been adequately evaluated in patients with hepatic impairment. Obese Patients The pharmacokinetics of glimepiride and its metabolites were measured in a single-dose study involving 28 patients with type 2 diabetes who either had normal body weight or were morbidly obese. While the t max , clearance, and volume of distribution of glimepiride in the morbidly obese patients were similar to those in the normal weight group, the morbidly obese had lower C max and AUC than those of normal body weight. The mean C max , AUC 0-24 , AUC 0-∞ values of glimepiride in normal vs. morbidly obese patients were 547 ± 218 ng/mL vs. 410 ± 124 ng/mL, 3210 ± 1030 hours·ng/mL vs. 2820 ± 1110 hours·ng/mL and 4000 ± 1320 hours·ng/mL vs. 3280 ± 1360 hours·ng/mL, respectively. Drug Interactions Aspirin In a randomized, double-blind, two-period, crossover study, healthy subjects were given either placebo or aspirin 1 gram three times daily for a total treatment period of 5 days. On Day 4 of each study period, a single 1 mg dose of glimepiride tablets was administered. The glimepiride tablets doses were separated by a 14-day washout period. Coadministration of aspirin and glimepiride resulted in a 34% decrease in the mean glimepiride AUC and a 4% decrease in the mean glimepiride C max . Colesevelam Concomitant administration of colesevelam and glimepiride resulted in reductions in glimepiride AUC 0-∞ and C max of 18% and 8%, respectively. When glimepiride was administered 4 hours prior to colesevelam, there was no significant change in glimepiride AUC 0-∞ or C max , -6% and 3%, respectively [see Dosage and Administration (2.1) and Drug Interactions (7.4) ]. Cimetidine and Ranitidine In a randomized, open-label, 3-way crossover study, healthy subjects received either a single 4 mg dose of glimepiride tablets alone, glimepiride with ranitidine (150 mg twice daily for 4 days; glimepiride was administered on Day 3), or glimepiride with cimetidine (800 mg daily for 4 days; glimepiride was administered on Day 3). Co-administration of cimetidine or ranitidine with a single 4 mg oral dose of glimepiride tablets did not significantly alter the absorption and disposition of glimepiride. Propranolol In a randomized, double-blind, two-period, crossover study, healthy subjects were given either placebo or propranolol 40 mg three times daily for a total treatment period of 5 days. On Day 4 of each study period, a single 2 mg dose of glimepiride tablets was administered. The glimepiride tablets doses were separated by a 14-day washout period. Concomitant administration of propranolol and glimepiride significantly increased glimepiride C max , AUC, and T 1/2 by 23%, 22%, and 15%, respectively, and decreased glimepiride CL/f by 18%. The recovery of M1 and M2 from urine was not changed. Warfarin In an open-label, two-way, crossover study, healthy subjects received 4 mg of glimepiride tablets daily for 10 days. Single 25 mg doses of warfarin were administered 6 days before starting glimepiride and on Day 4 of glimepiride administration. The concomitant administration of glimepiride did not alter the pharmacokinetics of R- and S-warfarin enantiomers. No changes were observed in warfarin plasma protein binding. Glimepiride resulted in a statistically significant decrease in the pharmacodynamic response to warfarin. The reductions in mean area under the prothrombin time (PT) curve and maximum PT values during glimepiride treatment were 3.3% and 9.9%, respectively, and are unlikely to be clinically relevant."],"indications_and_usage":["1 INDICATIONS AND USAGE Glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical Studies (14.1) ]. Limitations of Use Glimepiride tablets should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings. Glimepiride tablets are a sulfonylurea indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus ( 1 ). Limitations of Use: Not for treating type 1 diabetes mellitus or diabetic ketoacidosis ( 1 )."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Hypoglycemia: May be severe. Ensure proper patient selection, dosing, and instructions, particularly in at-risk populations (e.g., elderly, renally impaired) and when used with other anti-diabetic medications ( 5.1 ). Hypersensitivity Reactions: Postmarketing reports include anaphylaxis, angioedema and Stevens-Johnson Syndrome. If a reaction is suspected, promptly discontinue glimepiride, assess for other potential causes for the reaction, and institute alternative treatment for diabetes ( 5.2 ). Hemolytic Anemia: Can occur if glucose 6-phosphate dehydrogenase (G6PD) deficient. Consider a non-sulfonylurea alternative. ( 5.3 ). Potential Increased Risk of Cardiovascular Mortality with Sulfonylureas: Inform patient of risks, benefits and treatment alternatives ( 5.4 ). Macrovascular Outcomes: No clinical studies establishing conclusive evidence of macrovascular risk reduction with glimepiride or any other anti-diabetic drug ( 5.5 ). 5.1 Hypoglycemia All sulfonylureas, including glimepiride, can cause severe hypoglycemia [see Adverse Reactions (6.1) ]. The patient's ability to concentrate and react may be impaired as a result of hypoglycemia. These impairments may present a risk in situations where these abilities are especially important, such as driving or operating other machinery. Severe hypoglycemia can lead to unconsciousness or convulsions and may result in temporary or permanent impairment of brain function or death. Patients must be educated to recognize and manage hypoglycemia. Use caution when initiating and increasing glimepiride tablets doses in patients who may be predisposed to hypoglycemia (e.g., the elderly, patients with renal impairment, patients on other anti-diabetic medications). Debilitated or malnourished patients, and those with adrenal, pituitary, or hepatic impairment are particularly susceptible to the hypoglycemic action of glucose-lowering medications. Hypoglycemia is also more likely to occur when caloric intake is deficient, after severe or prolonged exercise, or when alcohol is ingested. Early warning symptoms of hypoglycemia may be different or less pronounced in patients with autonomic neuropathy, the elderly, and in patients who are taking beta-adrenergic blocking medications or other sympatholytic agents. These situations may result in severe hypoglycemia before the patient is aware of the hypoglycemia. 5.2 Hypersensitivity Reactions There have been postmarketing reports of hypersensitivity reactions in patients treated with glimepiride, including serious reactions such as anaphylaxis, angioedema, and Stevens-Johnson Syndrome [see Adverse Reactions (6.2) ]. If a hypersensitivity reaction is suspected, promptly discontinue glimepiride, assess for other potential causes for the reaction, and institute alternative treatment for diabetes. 5.3 Hemolytic Anemia Sulfonylureas can cause hemolytic anemia in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency. Because glimepiride tablets are a sulfonylurea, use caution in patients with G6PD deficiency and consider the use of a non-sulfonylurea alternative. There are also postmarketing reports of hemolytic anemia in patients receiving glimepiride who did not have known G6PD deficiency [see Adverse Reactions (6.2) ]. 5.4 Increased Risk of Cardiovascular Mortality with Sulfonylureas The administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term, prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. The study involved 823 patients who were randomly assigned to one of four treatment groups. UGDP reported that patients treated for 5 to 8 years with diet plus a fixed dose of tolbutamide (1.5 grams per day) had a rate of cardiovascular mortality approximately 2 and a half times that of patients treated with diet alone. A significant increase in total mortality was not observed, but the use of tolbutamide was discontinued based on the increase in cardiovascular mortality, thus limiting the opportunity for the study to show an increase in overall mortality. Despite controversy regarding the interpretation of these results, the findings of the UGDP study provide an adequate basis for this warning. The patient should be informed of the potential risks and advantages of glimepiride and of alternative modes of therapy. Although only one drug in the sulfonylurea class (tolbutamide) was included in this study, it is prudent from a safety standpoint to consider that this warning may also apply to other oral hypoglycemic drugs in this class, in view of their close similarities in mode of action and chemical structure. 5.5 Macrovascular Outcomes There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with glimepiride or any other anti-diabetic drug."],"clinical_studies_table":["
Table 3. 14-week Monotherapy Trial Comparing Glimepiride to Placebo in Patients Previously Treated With Sulfonylurea Therapy Intent-to-treat population using last observation on study
Placebo (N=74)Glimepiride
1 mg (N=78)4 mg (N=76)8 mg (N=76)
HbA 1C (%)
n=59n=65n=65n=68
Baseline (mean)87.97.98
Change from Baseline (adjusted mean Least squares mean adjusted for baseline value) 1.50.3-0.3-0.4
Difference from Placebo (adjusted mean ) 95% confidence interval -1.2 p<0.001 (-1.5, -0.8) -1.8 (-2.1, -1.4) -1.8 (-2.2, -1.5)
Mean Baseline Weight (kg)
n=67n=76n=75n=73
Baseline (mean)85.784.386.185.5
Change from Baseline (adjusted mean ) -2.3-0.20.51
Difference from Placebo (adjusted mean ) 95% confidence interval 2 (1.4, 2.7) 2.8 (2.1, 3.5) 3.2 (2.5, 4)
","
Table 4. 22-Week Monotherapy Trial Comparing Glimepiride to Placebo in Patients Who Were Treatment-Naïve or Who Had No Recent Treatment with Antidiabetic Therapy Intent to treat population using last observation on study
Placebo (N=126)Glimepiride (N=123)
HbA 1C (%) n=97n=106
Baseline (mean)9.19.3
Change from Baseline (adjusted mean Least squares mean adjusted for baseline value) -1.1 p<0.0001-2.2
Difference from Placebo (adjusted mean ) 95% confidence interval -1.1 (-1.5, -0.8)
Body Weight (kg)
n=122n=119
Baseline (mean)86.587.1
Change from Baseline (adjusted mean ) -0.91.8
Difference from Placebo (adjusted mean ) 95% confidence interval 2.7 (1.9, 3.6)
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Studies in rats at doses of up to 5000 parts per million (ppm) in complete feed (approximately 340 times the maximum recommended human dose, based on surface area) for 30 months showed no evidence of carcinogenesis. In mice, administration of glimepiride for 24 months resulted in an increase in benign pancreatic adenoma formation that was dose-related and was thought to be the result of chronic pancreatic stimulation. No adenoma formation in mice was observed at a dose of 320 ppm in complete feed, or 46 to 54 mg/kg body weight/day. This is at least 28 times the maximum human recommended dose of 8 mg once daily based on surface area. Glimepiride was non-mutagenic in a battery of in vitro and in vivo mutagenicity studies (Ames test, somatic cell mutation, chromosomal aberration, unscheduled DNA synthesis, and mouse micronucleus test). There was no effect of glimepiride on male mouse fertility in animals exposed up to 2,500 mg/kg body weight (>1,500 times the maximum recommended human dose based on surface area). Glimepiride had no effect on the fertility of male and female rats administered up to 4,000 mg/kg body weight (approximately 4,000 times the maximum recommended human dose based on surface area)."],"adverse_reactions_table":["
Table 1. Eleven Pooled Placebo-Controlled Trials ranging from 13 weeks to 12 months: Adverse Events (excluding hypoglycemia) Occurring in ≥5% of glimepiride-treated Patients and at a Greater Incidence than with Placebo Glimepiride doses ranged from 1 to 16 mg administered daily
GlimepirideN=745 %PlaceboN=294 %
Headache8.27.8
Accidental Injury Insufficient information to determine whether any of the accidental injury events were associated with hypoglycemia5.83.4
Flu Syndrome5.44.4
Nausea53.4
Dizziness52.4
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Hypoglycemia Explain the symptoms and treatment of hypoglycemia as well as conditions that predispose to hypoglycemia. Inform patients that their ability to concentrate and react may be impaired as a result of hypoglycemia and that this may present a risk in situations where these abilities are especially important, such as driving or operating other machinery [see Warnings and Precautions (5.1) ]. Hypersensitivity Reactions Inform patients that hypersensitivity reactions may occur with glimepiride and that if a reaction occurs to seek medical treatment and discontinue glimepiride [see Warnings and Precautions (5.2) ]. Pregnancy Advise females of reproductive potential to inform their prescriber of a known or suspected pregnancy [see Use in Specific Populations (8.1) ]. Lactation Advise breastfeeding women taking glimepiride tablets to monitor breastfed infants for signs of hypoglycemia (e.g., jitters, cyanosis, apnea, hypothermia, excessive sleepiness, poor feeding, seizures) [see Use in Specific Populations (8.2) ]. Rx only"],"spl_unclassified_section":["PACKAGING INFORMATION American Health Packaging unit dose blisters (see How Supplied section) contain drug product from Dr. Reddy's Laboratories Limited as follows: (1 mg / 30 UD) NDC 68084-788-25 packaged from NDC 55111-320 (2 mg / 100 UD) NDC 68084-326-01 packaged from NDC 55111-321 (4 mg / 100 UD) NDC 68084-327-01 packaged from NDC 55111-322 Distributed by: American Health Packaging Columbus, OH 43217 8232601/0721"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Recommended starting dose is 1 or 2 mg once daily. Increase in 1 or 2 mg increments no more frequently than every 1 to 2 weeks based on glycemic response. Maximum recommended dose is 8 mg once daily ( 2.1 ). Administer with breakfast or first meal of the day ( 2.1 ). Use 1 mg starting dose and titrate slowly in patients at increased risk for hypoglycemia (e.g., elderly, patients with renal impairment) ( 2.1 ). 2.1 Recommended Dosing Glimepiride tablets should be administered with breakfast or the first main meal of the day. The recommended starting dose of glimepiride tablets are 1 mg or 2 mg once daily. Patients at increased risk for hypoglycemia (e.g., the elderly or patients with renal impairment) should be started on 1 mg once daily [see Warnings and Precautions (5.1) and Use in Specific Populations (8.5 , 8.6) ]. After reaching a daily dose of 2 mg, further dose increases can be made in increments of 1 mg or 2 mg based upon the patient’s glycemic response. Uptitration should not occur more frequently than every 1 to 2 weeks. A conservative titration scheme is recommended for patients at increased risk for hypoglycemia [see Warnings and Precautions (5.1) and Use in Specific Populations (8.5 , 8.6) ]. The maximum recommended dose is 8 mg once daily. Patients being transferred to glimepiride tablets from longer half-life sulfonylureas (e.g., chlorpropamide) may have overlapping drug effect for 1 to 2 weeks and should be appropriately monitored for hypoglycemia. When colesevelam is coadministered with glimepiride, maximum plasma concentration and total exposure to glimepiride is reduced. Therefore, glimepiride tablets should be administered at least 4 hours prior to colesevelam."],"spl_product_data_elements":["Glimepiride Glimepiride LACTOSE MONOHYDRATE MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE POVIDONE, UNSPECIFIED SODIUM STARCH GLYCOLATE TYPE A POTATO FERRIC OXIDE RED GLIMEPIRIDE GLIMEPIRIDE Peach RDY;3;20 Glimepiride Glimepiride LACTOSE MONOHYDRATE MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE POVIDONE, UNSPECIFIED SODIUM STARCH GLYCOLATE TYPE A POTATO D&C YELLOW NO. 10 FD&C BLUE NO. 1 GLIMEPIRIDE GLIMEPIRIDE RDY;3;21 Glimepiride Glimepiride LACTOSE MONOHYDRATE MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE POVIDONE, UNSPECIFIED SODIUM STARCH GLYCOLATE TYPE A POTATO D&C YELLOW NO. 10 FD&C BLUE NO. 1 GLIMEPIRIDE GLIMEPIRIDE RDY;3;22"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Glimepiride tablets USP, are formulated as tablets of: Glimepiride tablets USP, 1 mg are peach, oval, flat beveled edged, uncoated tablets debossed “RDY” on one side and “320” separating “3” and “20” with bisect line scoring on the other side. Glimepiride tablets USP, 2 mg are green, oval, flat beveled edged, uncoated tablets debossed “RDY” on one side and “321” separating “3” and “21” with bisect line scoring on the other side. Glimepiride tablets USP, 4 mg are blue, oval, flat beveled edged, uncoated tablets debossed “RDY” on one side and “322” separating “3” and “22” with bisect line scoring on the other side. Tablets (scored): 1 mg, 2 mg, 4 mg ( 3 )"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Pediatric Patients: Not recommended because of adverse effects on body weight and hypoglycemia ( 8.4 ). Geriatric or Renally Impaired Patients: At risk for hypoglycemia with glimepiride. Use caution in dose selection and titration, and monitor closely ( 8.5 , 8.6 ). 8.1 Pregnancy Risk Summary Available data from a small number of published studies and postmarketing experience with glimepiride use in pregnancy over decades have not identified any drug associated risks for major birth defects, miscarriage, or adverse maternal outcomes. However, sulfonylureas (including glimepiride) cross the placenta and have been associated with neonatal adverse reactions such as hypoglycemia. Therefore, glimepiride tablets should be discontinued at least two weeks before expected delivery (see Clinical Considerations). Poorly controlled diabetes in pregnancy is also associated with risks to the mother and fetus (see Clinical Considerations). In animal studies (see Data), there were no effects on embryo-fetal development following administration of glimepiride to pregnant rats and rabbits at oral doses approximately 4,000 times and 60 times the maximum human dose based on body surface area, respectively. However, fetotoxicity was observed in rats and rabbits at doses 50 times and 0.1 times the maximum human dose, respectively. The estimated background risk of major birth defects is 6% to 10% in women with pregestational diabetes with a HbA 1c >7% and has been reported to be as high as 20% to 25% in women with a HbA 1c >10%. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo-fetal risk Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, preeclampsia, spontaneous abortions, preterm delivery, and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, still birth, and macrosomia-related morbidity. Fetal/neonatal adverse reactions Neonates of women with gestational diabetes who are treated with sulfonylureas during pregnancy may be at increased risk for neonatal intensive care admission and may develop respiratory distress, hypoglycemia, birth injury, and be large for gestational age. Prolonged severe hypoglycemia, lasting 4 to 10 days, has been reported in neonates born to mothers receiving a sulfonylurea at the time of delivery and has been reported with the use of agents with a prolonged half-life. Observe newborns for symptoms of hypoglycemia and respiratory distress and manage accordingly. Dose adjustments during pregnancy and the postpartum period Due to reports of prolonged severe hypoglycemia in neonates born to mothers receiving a sulfonylurea at the time of delivery, glimepiride tablets should be discontinued at least two weeks before expected delivery (see Fetal/Neonatal Adverse Reactions). Data Animal data In animal studies, there was no increase in congenital anomalies, but an increase in fetal deaths occurred in rats and rabbits at glimepiride doses 50 times (rats) and 0.1 times (rabbits) the maximum recommended human dose (based on body surface area). This fetotoxicity was observed only at doses inducing maternal hypoglycemia and is believed to be directly related to the pharmacologic (hypoglycemic) action of glimepiride, as has been similarly noted with other sulfonylureas. 8.2 Lactation Risk Summary Breastfed infants of lactating women using glimepiride tablets should be monitored for symptoms of hypoglycemia (see Clinical Considerations). It is not known whether glimepiride is excreted in human milk and there are no data on the effects of glimepiride on milk production. Glimepiride is present in rat milk [see Data]. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for glimepiride and any potential adverse effects on the breastfed child from glimepiride or from the underlying maternal condition. Clinical Considerations Monitoring for adverse reactions Monitor breastfed infants for signs of hypoglycemia (e.g., jitters, cyanosis, apnea, hypothermia, excessive sleepiness, poor feeding, seizures). Data During prenatal and postnatal studies in rats, significant concentrations of glimepiride were present in breast milk and the serum of the pups. Offspring of rats exposed to high levels of glimepiride during pregnancy and lactation developed skeletal deformities consisting of shortening, thickening, and bending of the humerus during the postnatal period. These skeletal deformations were determined to be the result of nursing from mothers exposed to glimepiride. 8.4 Pediatric Use The pharmacokinetics, efficacy and safety of glimepiride have been evaluated in pediatric patients with type 2 diabetes as described below. Glimepiride tablets are not recommended in pediatric patients because of its adverse effects on body weight and hypoglycemia. The pharmacokinetics of a 1 mg single dose of glimepiride was evaluated in 30 patients with type 2 diabetes (male = 7; female = 23) between ages 10 and 17 years. The mean (± SD) AUC (0-last) (339±203 ng•hr/mL), C max (102±48 ng/mL) and t 1/2 (3.1±1.7 hours) for glimepiride were comparable to historical data from adults (AUC (0-last) 315±96 ng•hr/mL, C max 103±34 ng/mL and t 1/2 5.3±4.1 hours). The safety and efficacy of glimepiride in pediatric patients was evaluated in a single-blind, 24-week trial that randomized 272 patients (8 to 17 years of age) with type 2 diabetes to glimepiride (n=135) or metformin (n=137). Both treatment-naïve patients (those treated with only diet and exercise for at least 2 weeks prior to randomization) and previously treated patients (those previously treated or currently treated with other oral antidiabetic medications for at least 3 months) were eligible to participate. Patients who were receiving oral antidiabetic agents at the time of study entry discontinued these medications before randomization without a washout period. Glimepiride was initiated at 1 mg, and then titrated up to 2, 4 or 8 mg (mean last dose 4 mg) through Week 12, targeting a self-monitored fasting fingerstick blood glucose < 126 mg/dL. Metformin was initiated at 500 mg twice daily and titrated at Week 12 up to 1000 mg twice daily (mean last dose 1365 mg). After 24 weeks, the overall mean treatment difference in HbA 1c between glimepiride and metformin was 0.2%, favoring metformin (95% confidence interval -0.3% to +0.6%). Based on these results, the trial did not meet its primary objective of showing a similar reduction in HbA 1c with glimepiride compared to metformin. Table 2. Change from Baseline in HbA 1C and Body Weight in Pediatric Patients Taking Glimepiride or Metformin Metformin Glimepiride Treatment-Naïve Patients Intent-to-treat population using last-observation-carried-forward for missing data (Glimepiride, n=127; metformin, n=126) N=69 N=72 HbA 1C (%) Baseline (mean) 8.2 8.3 Change from baseline (adjusted LS mean) adjusted for baseline HbA1c and Tanner Stage -1.2 -1 Adjusted Treatment Difference Difference is glimepiride – metformin with positive differences favoring metformin (95% CI) 0.2 (-0.3; 0.6) Previously Treated Patients N=57 N=55 HbA 1C (%) Baseline (mean) 9 8.7 Change from baseline (adjusted LS mean) -0.2 0.2 Adjusted Treatment Difference (95% CI) 0.4 (-0.4; 1.2) Body Weight (kg) N=126 N=129 Baseline (mean) 67.3 66.5 Change from baseline (adjusted LS mean) 0.7 2 Adjusted Treatment Difference (95% CI) 1.3 (0.3; 2.3) The profile of adverse reactions in pediatric patients treated with glimepiride was similar to that observed in adults [see Adverse Reactions (6) ]. Hypoglycemic events documented by blood glucose values <36 mg/dL were observed in 4% of pediatric patients treated with glimepiride and in 1% of pediatric patients treated with metformin. One patient in each treatment group experienced a severe hypoglycemic episode (severity was determined by the investigator based on observed signs and symptoms). 8.5 Geriatric Use In clinical trials of glimepiride, 1053 of 3491 patients (30%) were >65 years of age. No overall differences in safety or effectiveness were observed between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out. There were no significant differences in glimepiride pharmacokinetics between patients with type 2 diabetes ≤65 years (n=49) and those >65 years (n=42) [see Clinical Pharmacology (12.3) ]. Glimepiride is substantially excreted by the kidney. Elderly patients are more likely to have renal impairment. In addition, hypoglycemia may be difficult to recognize in the elderly [see Dosage and Administration (2.1) and Warnings and Precautions (5.1) ]. Use caution when initiating glimepiride and increasing the dose of glimepiride tablets in this patient population. 8.6 Renal Impairment To minimize the risk of hypoglycemia, the recommended starting dose of glimepiride tablets are 1 mg daily for all patients with type 2 diabetes and renal impairment [see Dosage and Administration (2.1) and Warnings and Precautions (5.1) ]. A multiple-dose titration study was conducted in 16 patients with type 2 diabetes and renal impairment using doses ranging from 1 mg to 8 mg daily for 3 months. Baseline creatinine clearance ranged from 10 to 60 mL/min. The pharmacokinetics of glimepiride tablets were evaluated in the multiple-dose titration study and the results were consistent with those observed in patients enrolled in a single-dose study. In both studies, the relative total clearance of glimepiride increased when kidney function was impaired. Both studies also demonstrated that the elimination of the two major metabolites was reduced in patients with renal impairment [see Clinical Pharmacology (12.3) ]."],"use_in_specific_populations_table":["
Table 2. Change from Baseline in HbA 1C and Body Weight in Pediatric Patients Taking Glimepiride or Metformin
MetforminGlimepiride
Treatment-Naïve PatientsIntent-to-treat population using last-observation-carried-forward for missing data (Glimepiride, n=127; metformin, n=126)N=69N=72
HbA 1C (%)
Baseline (mean)8.28.3
Change from baseline (adjusted LS mean) adjusted for baseline HbA1c and Tanner Stage -1.2-1
Adjusted Treatment Difference Difference is glimepiride – metformin with positive differences favoring metformin (95% CI) 0.2 (-0.3; 0.6)
Previously Treated PatientsN=57N=55
HbA 1C (%)
Baseline (mean)98.7
Change from baseline (adjusted LS mean) -0.20.2
Adjusted Treatment Difference (95% CI) 0.4 (-0.4; 1.2)
Body Weight (kg)N=126N=129
Baseline (mean)67.366.5
Change from baseline (adjusted LS mean) 0.72
Adjusted Treatment Difference (95% CI) 1.3 (0.3; 2.3)
"],"package_label_principal_display_panel":["Package/Label Display Panel – Carton – 1 mg NDC 68084- 788 -25 ONCE A DAY Glimepiride Tablets, USP 1 mg 30 Tablets (5 x 6) Rx Only Each Tablet Contains: Glimepiride USP...................................................1 mg Usual Dosage: See full prescribing information. Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. FOR YOUR PROTECTION: Do not use if blister is torn or broken. The drug product contained in this package is from NDC # 55111-320, Dr. Reddy’s Laboratories Limited. Distributed by: American Health Packaging, Columbus, Ohio 43217 078825 0278825/1024 1 mg Glimepiride Tablets Carton","Package/Label Display Panel – Blister – 1 mg Glimepiride Tablet, USP ONCE A DAY 1 mg 1 mg Glimepiride Tablet Blister","Package/Label Display Panel – Carton – 2 mg NDC 68084- 326 -01 ONCE A DAY Glimepiride Tablets, USP 2 mg 100 Tablets (10 x 10) Rx Only Each Tablet Contains: Glimepiride USP.......................................................................... 2 mg Usual Dosage: See full prescribing information. Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. FOR YOUR PROTECTION: Do not use if blister is torn or broken. The drug product contained in this package is from NDC # 55111-321, Dr. Reddy’s Laboratories Limited. Distributed by: American Health Packaging, Columbus, Ohio 43217 032601 0232601/1024 2 mg Glimepiride Tablets Carton","Package/Label Display Panel – Blister – 2 mg ONCE A DAY Glimepiride Tablet, USP 2 mg 2 mg Glimepiride Tablet Blister","Package/Label Display Panel – Carton – 4 mg NDC 68084- 327 -01 ONCE A DAY Glimepiride Tablets, USP 4 mg 100 Tablets (10 x 10) Rx Only Each Tablet Contains: Glimepiride USP.......................................................................... 4 mg Usual Dosage: See full prescribing information. Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. FOR YOUR PROTECTION: Do not use if blister is torn or broken. The drug product contained in this package is from NDC # 55111-322, Dr. Reddy’s Laboratories Limited. Distributed by: American Health Packaging, Columbus, Ohio 43217 032701 0232701/1024 4 mg Glimepiride Tablets Carton","Package/Label Display Panel – Blister – 4 mg Glimepiride Tablet, USP ONCE A DAY 4 mg 4 mg Glimepiride Tablet Blister"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Studies in rats at doses of up to 5000 parts per million (ppm) in complete feed (approximately 340 times the maximum recommended human dose, based on surface area) for 30 months showed no evidence of carcinogenesis. In mice, administration of glimepiride for 24 months resulted in an increase in benign pancreatic adenoma formation that was dose-related and was thought to be the result of chronic pancreatic stimulation. No adenoma formation in mice was observed at a dose of 320 ppm in complete feed, or 46 to 54 mg/kg body weight/day. This is at least 28 times the maximum human recommended dose of 8 mg once daily based on surface area. Glimepiride was non-mutagenic in a battery of in vitro and in vivo mutagenicity studies (Ames test, somatic cell mutation, chromosomal aberration, unscheduled DNA synthesis, and mouse micronucleus test). There was no effect of glimepiride on male mouse fertility in animals exposed up to 2,500 mg/kg body weight (>1,500 times the maximum recommended human dose based on surface area). Glimepiride had no effect on the fertility of male and female rats administered up to 4,000 mg/kg body weight (approximately 4,000 times the maximum recommended human dose based on surface area)."]},"tags":[{"label":"Sulfonylurea","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Sulfonylurea receptor 1, Kir6.2","category":"target"},{"label":"ABCC8","category":"gene"},{"label":"KCNJ11","category":"gene"},{"label":"ABCC9","category":"gene"},{"label":"A10BB12","category":"atc"},{"label":"Oral","category":"route"},{"label":"Tablet","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Diabetes mellitus type 2","category":"indication"},{"label":"Treatment Refractory Type 2 Diabetes Mellitus","category":"indication"},{"label":"Sanofi Aventis Us","category":"company"},{"label":"Approved 1990s","category":"decade"},{"label":"Anti-Arrhythmia Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Hypoglycemic Agents","category":"pharmacology"},{"label":"Immunologic Factors","category":"pharmacology"},{"label":"Immunosuppressive Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"BLOOD GLUCOSE INCREASED","source":"FDA FAERS","actionTaken":"2980 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"2282 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"2172 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"1925 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"1830 reports"},{"date":"","signal":"HYPOGLYCAEMIA","source":"FDA FAERS","actionTaken":"1642 reports"},{"date":"","signal":"WEIGHT DECREASED","source":"FDA FAERS","actionTaken":"1395 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"1370 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"1327 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"1293 reports"}],"drugInteractions":[{"url":"/drug/ciprofloxacin","drug":"ciprofloxacin","action":"Monitor closely","effect":"May interact with Ciprofloxacin","source":"DrugCentral","drugSlug":"ciprofloxacin"},{"url":"/drug/levofloxacin","drug":"levofloxacin","action":"Monitor closely","effect":"May interact with Levofloxacin","source":"DrugCentral","drugSlug":"levofloxacin"},{"url":"/drug/norfloxacin","drug":"norfloxacin","action":"Monitor closely","effect":"May interact with Norfloxacin","source":"DrugCentral","drugSlug":"norfloxacin"},{"url":"/drug/ofloxacin","drug":"ofloxacin","action":"Monitor closely","effect":"May interact with Ofloxacin","source":"DrugCentral","drugSlug":"ofloxacin"},{"url":"/drug/voriconazole","drug":"voriconazole","action":"Monitor closely","effect":"May interact with Voriconazole","source":"DrugCentral","drugSlug":"voriconazole"}],"commonSideEffects":[{"effect":"Hypoglycemia","drugRate":"17%","severity":"serious","_validated":true},{"effect":"Headache","drugRate":"8.2%","severity":"common","_validated":true},{"effect":"Accidental Injury","drugRate":"5.8%","severity":"common","_validated":true},{"effect":"Flu Syndrome","drugRate":"5.4%","severity":"common","_validated":true},{"effect":"Nausea","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Dizziness","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Weight gain","drugRate":"reported","severity":"unknown"},{"effect":"Elevated serum alanine aminotransferase (ALT)","drugRate":"1.9%","severity":"mild","_validated":true},{"effect":"Allergic Reactions","drugRate":"reported","severity":"unknown"},{"effect":"Pruritus","drugRate":"reported","severity":"unknown"},{"effect":"Erythema","drugRate":"reported","severity":"unknown"},{"effect":"Urticaria","drugRate":"reported","severity":"unknown"},{"effect":"Morbilliform or maculopapular eruptions","drugRate":"reported","severity":"unknown"},{"effect":"Hemolytic anemia","drugRate":"reported","severity":"unknown"},{"effect":"Impairment of liver function","drugRate":"reported","severity":"unknown"},{"effect":"Hepatitis","drugRate":"reported","severity":"unknown"},{"effect":"Porphyria cutanea tarda","drugRate":"reported","severity":"unknown"},{"effect":"Photosensitivity reactions","drugRate":"reported","severity":"unknown"},{"effect":"Allergic vasculitis","drugRate":"reported","severity":"unknown"},{"effect":"Leukopenia","drugRate":"reported","severity":"unknown"},{"effect":"Agranulocytosis","drugRate":"reported","severity":"unknown"},{"effect":"Aplastic anemia","drugRate":"reported","severity":"unknown"},{"effect":"Pancytopenia","drugRate":"reported","severity":"unknown"},{"effect":"Thrombocytopenia","drugRate":"reported","severity":"unknown"},{"effect":"Thrombocytopenic purpura","drugRate":"reported","severity":"unknown"},{"effect":"Hepatic porphyria reactions","drugRate":"reported","severity":"unknown"},{"effect":"Disulfiram-like reactions","drugRate":"reported","severity":"unknown"},{"effect":"Hyponatremia","drugRate":"reported","severity":"unknown"},{"effect":"Syndrome of inappropriate antidiuretic hormone secretion (SIADH)","drugRate":"reported","severity":"unknown"},{"effect":"Dysgeusia","drugRate":"reported","severity":"unknown"}],"contraindications":["Alcoholism","Angina pectoris","Asthenia","Autonomic dysreflexia","Body fluid retention","Breastfeeding (mother)","Cerebrovascular accident","Chronic heart failure","Decompensated cardiac failure","Disease of liver","Disorder of coronary artery","Drug-induced hepatitis","Edema","Fever","Fever greater than 100.4 Fahrenheit","Fracture of bone","Glucose-6-phosphate dehydrogenase deficiency anemia","Hemolytic anemia","Hepatic porphyria","Hypoglycemic disorder","Hypopituitarism","Infectious disease","Kidney disease","Liver function tests abnormal","Macular retinal edema"],"specialPopulations":{"Lactation":"Breastfed infants of lactating women using glimepiride tablets should be monitored for symptoms of hypoglycemia (see Clinical Considerations). It is not known whether glimepiride is excreted in human milk and there are no data on the effects of glimepiride on milk production. Glimepiride is present in rat milk [see Data]. The developmental and health benefits of breastfeeding should be considered along with the mothers clinical need for glimepiride and any potential adverse effects on the breastfed infant.","Pregnancy":"Glimepiride did not produce teratogenic effects in rats exposed orally up to 4000 mg/kg body weight (approximately 4,000 times the maximum recommended human dose based on surface area) or in rabbits exposed up to 32 mg/kg body weight (approximately 60 times the maximum recommended human dose based on surface area). Glimepiride has been shown to be associated with intrauterine fetal death in rats when given in doses as low as 50 times the human dose.","Geriatric use":"In US clinical studies of glimepiride, 608 of 1986 patients were 65 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, but greater sensitivity of some older individuals cannot be ruled out.Comparison of glimepiride pharmacokinetics in Type diabetic patients <=65 years (n=49) and those >65 years (n=42) was performed in study using dosing regimen of mg daily. There were no significant differences in glimepiride pharmacokinetics between the two groups.","Paediatric use":"The safety and efficacy of glimepiride were evaluated in an active-controlled, single-blind (patients only), 24-week trial involving 272 pediatric patients, ranging from to 17 years of age, with Type diabetes. Glimepiride (n=135) was administered at mg initially, and then titrated up to 2, or mg (mean last dose mg) until the therapeutic goal of self-monitored fasting blood glucose less than 7.0 mmol/L (less than 126 mg/dL) was achieved. The active comparator metformin (n=137) was "}},"trials":[],"aliases":[],"company":"Sanofi","patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.0258/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$9","description":"GLIMEPIRIDE 1 MG TABLET","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=GLIMEPIRIDE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:33:39.812279+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Glimepiride","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:33:48.337774+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:33:46.229217+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:33:38.938427+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GLIMEPIRIDE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:33:47.269253+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:33:36.695889+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:33:36.695928+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:33:36.695934+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:33:48.806375+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Sulfonylurea receptor 1, Kir6.2 blocker","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:33:48.337681+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1481/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:33:47.987779+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA077091","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:33:36.695937+00:00"}},"allNames":"amaryl","offLabel":[],"synonyms":["glimepiride","diameprid","glimax","glimperide","glirid"],"timeline":[{"date":"1995-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from SANOFI AVENTIS US to Sanofi Aventis Us"},{"date":"1995-11-30","type":"positive","source":"DrugCentral","milestone":"FDA approval (Sanofi Aventis Us)"},{"date":"2013-04-17","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 16 manufacturers approved"}],"aiSummary":"Amaryl (Glimepiride) is a sulfonylurea medication developed by Sanofi Aventis US, targeting the sulfonylurea receptor 1 (SUR1) and Kir6.2 subunit of the ATP-sensitive potassium channel. It is a small molecule modality, FDA-approved in 1995 for the treatment of type 2 diabetes mellitus and treatment-refractory type 2 diabetes mellitus. Amaryl is now off-patent with 17 generic manufacturers, offering a commercial alternative to branded options. Key safety considerations include hypoglycemia risk, particularly when combined with other diabetes medications. As a sulfonylurea, Amaryl works by stimulating insulin release from pancreatic beta cells.","approvals":[{"date":"1995-11-30","orphan":false,"company":"SANOFI AVENTIS US","regulator":"FDA"}],"brandName":"Amaryl","ecosystem":[{"indication":"Diabetes mellitus type 2","otherDrugs":[{"name":"acarbose","slug":"acarbose","company":"Bayer Hlthcare"},{"name":"acetohexamide","slug":"acetohexamide","company":"Lilly"},{"name":"albiglutide","slug":"albiglutide","company":"Glaxosmithkline Llc"},{"name":"alogliptin","slug":"alogliptin","company":"Takeda Pharms Usa"}],"globalPrevalence":537000000},{"indication":"Treatment Refractory Type 2 Diabetes Mellitus","otherDrugs":[{"name":"metformin","slug":"metformin","company":"Bristol Myers Squibb"},{"name":"rosiglitazone","slug":"rosiglitazone","company":"Sb Pharmco"}],"globalPrevalence":53000000}],"mechanism":{"target":"Sulfonylurea receptor 1, Kir6.2","novelty":"Follow-on","targets":[{"gene":"ABCC8","source":"DrugCentral","target":"Sulfonylurea receptor 1, Kir6.2","protein":"ATP-binding cassette sub-family C member 8"},{"gene":"KCNJ11","source":"DrugCentral","target":"Sulfonylurea receptor 1, Kir6.2","protein":"ATP-sensitive inward rectifier potassium channel 11"},{"gene":"ABCC9","source":"DrugCentral","target":"Sulfonylurea receptor 2, Kir6.2","protein":"ATP-binding cassette sub-family C member 9"},{"gene":"AKR1C3","source":"DrugCentral","target":"Aldo-keto reductase family 1 member C3","protein":"Aldo-keto reductase family 1 member C3"}],"modality":"Small Molecule","drugClass":"Sulfonylurea [EPC]","explanation":"Mechanism of Action. The primary mechanism of action of glimepiride in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells. In addition, extrapancreatic effects may also play role in the activity of sulfonylureas such as glimepiride. This is supported by both preclinical and clinical studies demonstrating that glimepiride administration can lead to increased sensitivity of peripheral tissues to insulin. These findings are consistent with the results of long-term, randomized, placebo-controlled trial in which glimepiride therapy improved postprandial insulin/C-peptide responses and overall glycemic control without producing clinically meaningful increases in fasting insulin/C-peptide levels. However, as with other sulfonylureas, the mechanism by which glimepiride lowers blood glucose during long-term administration has not been clearly established.Glimepiride is effective as initial drug therapy. In patients where m","oneSentence":"Amaryl works by binding to the sulfonylurea receptor 1 (SUR1) and Kir6.2 subunit of the ATP-sensitive potassium channel, closing the channel and depolarizing the pancreatic beta cell membrane, leading to insulin release.","technicalDetail":"Glimepiride binds to the SUR1 subunit of the ATP-sensitive potassium channel, which is a hetero-octameric complex composed of four Kir6.2 and four SUR1 subunits. This binding causes a conformational change in the channel, leading to its closure and depolarization of the pancreatic beta cell membrane, which triggers insulin release through the opening of voltage-dependent calcium channels and subsequent increase in intracellular calcium concentrations."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Glimepiride","title":"Glimepiride","extract":"Glimepiride is an antidiabetic medication within the sulfonylurea class, primarily prescribed for the management of type 2 diabetes. It is regarded as a second-line option compared to metformin, due to metformin's well-established safety and efficacy. Use of glimepiride is recommended in conjunction with lifestyle modifications such as diet and exercise. It is taken by mouth, reaching a peak effect within three hours and lasting for about a day."},"commercial":{"launchDate":"1995","_launchSource":"DrugCentral (FDA 1995-11-30, SANOFI AVENTIS US)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1300","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=GLIMEPIRIDE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GLIMEPIRIDE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Glimepiride","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T13:48:23.897155","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:34:03.673197+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"glibenclamide","drugSlug":"glibenclamide","fdaApproval":"1984-05-01","relationship":"same-class"},{"drugName":"chlorpropamide","drugSlug":"chlorpropamide","fdaApproval":"1958-10-28","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"tolbutamide","drugSlug":"tolbutamide","fdaApproval":"1961-06-22","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"tolazamide","drugSlug":"tolazamide","fdaApproval":"1966-07-18","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"glipizide","drugSlug":"glipizide","fdaApproval":"1984-05-08","genericCount":18,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"acetohexamide","drugSlug":"acetohexamide","fdaApproval":"1964-12-23","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"glimepiride","indications":{"approved":[{"name":"Diabetes mellitus type 2","source":"DrugCentral","snomedId":44054006,"regulator":"FDA","eligibility":"Adult patients with type 2 diabetes mellitus","usPrevalence":37300000,"globalPrevalence":537000000,"prevalenceMethod":"curated","prevalenceSource":"IDF Diabetes Atlas, 2024"},{"name":"Treatment Refractory Type 2 Diabetes Mellitus","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Adult patients with type 2 diabetes mellitus who have failed to achieve adequate glycemic control with one or more oral antidiabetic medications, including metformin, sulfonylureas, pioglitazone, and/or repaglinide","usPrevalence":null,"globalPrevalence":53000000,"prevalenceMethod":"curated","prevalenceSource":"IDF estimate, 2024"}],"offLabel":[],"pipeline":[]},"currentOwner":"Sanofi Aventis Us","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"glibenclamide","brandName":"glibenclamide","genericName":"glibenclamide","approvalYear":"1984","relationship":"same-class"},{"drugId":"chlorpropamide","brandName":"chlorpropamide","genericName":"chlorpropamide","approvalYear":"1958","relationship":"same-class"},{"drugId":"tolbutamide","brandName":"tolbutamide","genericName":"tolbutamide","approvalYear":"1961","relationship":"same-class"},{"drugId":"tolazamide","brandName":"tolazamide","genericName":"tolazamide","approvalYear":"1966","relationship":"same-class"},{"drugId":"glipizide","brandName":"glipizide","genericName":"glipizide","approvalYear":"1984","relationship":"same-class"},{"drugId":"acetohexamide","brandName":"acetohexamide","genericName":"acetohexamide","approvalYear":"1964","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT01794143","phase":"PHASE3","title":"A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes","status":"COMPLETED","sponsor":"GRADE Study Group","startDate":"2013-05","conditions":["Type 2 Diabetes","Comparative Effectiveness of Glycemia-lowering Medications"],"enrollment":7850,"completionDate":"2021-04-30"},{"nctId":"NCT07365358","phase":"PHASE4","title":"Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients","status":"NOT_YET_RECRUITING","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2026-03","conditions":["Diabete Type 2"],"enrollment":200,"completionDate":"2027-08"},{"nctId":"NCT00974090","phase":"PHASE3","title":"Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-09","conditions":["Type 2 Diabetes Mellitus"],"enrollment":194,"completionDate":"2011-03"},{"nctId":"NCT07288749","phase":"PHASE3","title":"Efficacy Evaluation of Glimepiride in Patients With Type 2 Diabetes Mellitus and Chronic Heart Failure With Reduced Ejection Fraction.","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2026-01-01","conditions":["Type 2 Diabetes Mellitus (T2DM)","Chronic Heart Failure (CHF)"],"enrollment":1484,"completionDate":"2031-12-31"},{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":["Cardiovascular Events","Type2 Diabetes","Renal Disease"],"enrollment":781430,"completionDate":"2026-07-01"},{"nctId":"NCT05073692","phase":"","title":"Comparison of Type 2 Diabetes Pharmacotherapy Regimens","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2021-07-01","conditions":["Type 2 Diabetes Mellitus","Cardiovascular Diseases"],"enrollment":241981,"completionDate":"2025-03-12"},{"nctId":"NCT06759922","phase":"PHASE4","title":"Glimepiride, Empagliflozin, and Sitagliptin With Metformin for Type 2 Diabetes","status":"COMPLETED","sponsor":"Bahria University","startDate":"2025-01-01","conditions":["Type 2 Diabetes Mellitus"],"enrollment":172,"completionDate":"2025-06-30"},{"nctId":"NCT03492580","phase":"","title":"A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-22","conditions":["Diabetes Mellitus, Type 2","Cardiovascular Diseases"],"enrollment":714582,"completionDate":"2018-06-25"},{"nctId":"NCT04841096","phase":"PHASE3","title":"Oral Combination of Glimepiride/Vildagliptin/Metformin in Patients With T2D and Dual Treatment Failure","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2023-03-21","conditions":["Type 2 Diabetes"],"enrollment":162,"completionDate":"2024-05-15"},{"nctId":"NCT01242215","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Sulfonylurea in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-09-17","conditions":["Type 2 Diabetes Mellitus"],"enrollment":243,"completionDate":"2012-04-25"},{"nctId":"NCT06068686","phase":"NA","title":"Vildagliptin Versus Glimepiride in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2022-10-01","conditions":["Type 2 Diabetes"],"enrollment":70,"completionDate":"2024-12-01"},{"nctId":"NCT03118713","phase":"PHASE4","title":"A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria","status":"TERMINATED","sponsor":"Astellas Pharma Korea, Inc.","startDate":"2017-04-25","conditions":["Type 2 Diabetes Mellitus"],"enrollment":33,"completionDate":"2018-12-12"},{"nctId":"NCT06644404","phase":"PHASE1","title":"Phase 1 Study of Drug-Drug Interactions Between DWP16001, DWC202407, and DWC202408 in Healthy Adults","status":"NOT_YET_RECRUITING","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2024-10-26","conditions":["Healthy"],"enrollment":34,"completionDate":"2025-04-01"},{"nctId":"NCT06570980","phase":"","title":"Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.","status":"RECRUITING","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2023-08-25","conditions":["Type 2 Diabetes Mellitus (T2DM), Cost-effectiveness, Sulfonylureas, DPP4 Inhibitors, Metformin"],"enrollment":200,"completionDate":"2024-08-30"},{"nctId":"NCT00835172","phase":"PHASE1","title":"Glimepiride 4 mg Tablets Under Non-Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2003-03","conditions":["Healthy"],"enrollment":32,"completionDate":"2003-03"},{"nctId":"NCT00834340","phase":"PHASE1","title":"Glimepiride 4 mg Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2003-02","conditions":["Healthy"],"enrollment":32,"completionDate":"2003-03"},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":["Type2diabetes"],"enrollment":938,"completionDate":"2025-06"},{"nctId":"NCT05975528","phase":"PHASE4","title":"Effect of Sodium-glucose Cotransporter-2 Inhibitor in Cellular Senescence in Patients With Cardiovascular Diseases or Type 2 Diabetes","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2023-06-01","conditions":["Diabetes Mellitus","Cellular Senescence","Sodium-Glucose Transporter 2 Inhibitors"],"enrollment":92,"completionDate":"2025-12-31"},{"nctId":"NCT00650533","phase":"PHASE1","title":"Food Study of Glimepiride Tablets 1 mg to Amaryl® Tablets 1 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2004-11","conditions":["Healthy"],"enrollment":40,"completionDate":"2004-12"},{"nctId":"NCT00648362","phase":"PHASE1","title":"Fasting Study of Glimepiride Tablets 1 mg to Amaryl® Tablets 1 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2004-11","conditions":["Healthy"],"enrollment":40,"completionDate":"2004-12"},{"nctId":"NCT03917940","phase":"NA","title":"Omega 3 Fatty Acids on Serum Irisin and Sirtuin-1 in Type 2 Diabetic Mellitus Patients Treated With Glimepiride","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2019-01-31","conditions":["Diabetic Patients"],"enrollment":70,"completionDate":"2020-05-10"},{"nctId":"NCT05162183","phase":"","title":"Replication of the LEAD-2 Diabetes Trial in Healthcare Claims Data","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2019-09-01","conditions":["Diabetes"],"enrollment":3474,"completionDate":"2021-09-01"},{"nctId":"NCT05099198","phase":"","title":"Replication of the GRADE Diabetes Trial in Healthcare Claims Data","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2018-09-01","conditions":["Diabetes"],"enrollment":6403,"completionDate":"2021-08-01"},{"nctId":"NCT01951339","phase":"NA","title":"Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2013-10","conditions":["Type 2 Diabetes","Cardiovascular Disease"],"enrollment":36,"completionDate":"2018-06"},{"nctId":"NCT05161429","phase":"","title":"BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-07-01","conditions":["Diabetes Mellitus, Type 2"],"enrollment":550000,"completionDate":"2024-06-30"},{"nctId":"NCT03693560","phase":"PHASE4","title":"Effect of Adding Vildagliptin vs Glimepiride to Metformin on Inflammation's Markers in Type-2 Diabetic Patients With CAD","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2018-10-08","conditions":["Coronary Artery Disease","Diabetes Mellitus, Type 2"],"enrollment":80,"completionDate":"2019-10-10"},{"nctId":"NCT04240171","phase":"","title":"Dapagliflozin Versus Glimepiride Effect in Patient With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2020-12-01","conditions":["Diabetes Mellitus, Type 2"],"enrollment":60,"completionDate":"2022-01-31"},{"nctId":"NCT03907423","phase":"NA","title":"Rosuvastatin on Diabetic Patients Treated With Glimepiride/Metformin","status":"COMPLETED","sponsor":"Rehab Werida","startDate":"2019-04-01","conditions":["Diabetes Mellitus, Type 2"],"enrollment":70,"completionDate":"2021-01-31"},{"nctId":"NCT05663736","phase":"PHASE4","title":"Effect of Gemigliptin Versus Glimepiride on Cardiac Diastolic Function in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2020-01-01","conditions":["Ejection Fraction"],"enrollment":80,"completionDate":"2023-12-31"},{"nctId":"NCT04183868","phase":"PHASE4","title":"Effects of empagliFlozin on myocardIal metabOlic Rate of glucosE Estimated Through 18FDG PET (FIORE Study)","status":"COMPLETED","sponsor":"University of Catanzaro","startDate":"2016-04","conditions":["Type 2 Diabetes","Cardiovascular Risk Factor"],"enrollment":26,"completionDate":"2021-10"},{"nctId":"NCT05538819","phase":"","title":"The Effects of Glimepiride in Patients With Type 2 Diabetes and Chronic Heart Failure","status":"COMPLETED","sponsor":"Dao Wen Wang","startDate":"2017-06-01","conditions":["Chronic Heart Failure","Type 2 Diabetes","Cardiovascular Mortality","Cohort Study"],"enrollment":1018,"completionDate":"2022-07-01"},{"nctId":"NCT03076112","phase":"PHASE3","title":"Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2017-04-25","conditions":["Type 2 Diabetes Mellitus"],"enrollment":170,"completionDate":"2022-08-31"},{"nctId":"NCT01131182","phase":"PHASE4","title":"Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-13","conditions":["Type 2 Diabetes Mellitus (T2DM)"],"enrollment":1147,"completionDate":"2010-11-04"},{"nctId":"NCT05468879","phase":"NA","title":"Bioequivalence Study of 3 mg Glimepiride Tablet in Indonesia Healthy Subjects","status":"COMPLETED","sponsor":"PT Harsen Laboratories","startDate":"2020-09-21","conditions":["Drug Use"],"enrollment":34,"completionDate":"2021-01-06"},{"nctId":"NCT05103306","phase":"","title":"Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy","status":"UNKNOWN","sponsor":"Chungbuk National University Hospital","startDate":"2017-01","conditions":["Diabetes Mellitus, Type 2"],"enrollment":300,"completionDate":"2022-12"},{"nctId":"NCT03748810","phase":"","title":"Head-to-head Comparison of Empagliflozin and Dapagliflozin","status":"COMPLETED","sponsor":"Chungbuk National University Hospital","startDate":"2016-01-01","conditions":["Type2 Diabetes"],"enrollment":600,"completionDate":"2022-06-30"},{"nctId":"NCT05162690","phase":"PHASE2,PHASE3","title":"Efficacy of Dapagliflozin in Diabetes Associated Peripheral Neuropathy","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2022-05-01","conditions":["Diabetic Peripheral Neuropathy"],"enrollment":40,"completionDate":"2023-12-31"},{"nctId":"NCT00775684","phase":"NA","title":"Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2008-10","conditions":["Pre-diabetes","Type 2 Diabetes"],"enrollment":47,"completionDate":"2012-11"},{"nctId":"NCT05386186","phase":"PHASE4","title":"The Effect of Glimepiride Compared With Sitagliptin as an add-on Therapy to Metformin in Severe Insulin Deficiency Diabetes","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2022-01-01","conditions":["Diabetes Mellitus, Type 2","Severe Insulin Deficient Diabetes"],"enrollment":192,"completionDate":"2024-03-31"},{"nctId":"NCT04528212","phase":"PHASE4","title":"Fenofibrate Versus Curcumin in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Rehab Werida","startDate":"2020-11-01","conditions":["Diabetes Mellitus, Type 2"],"enrollment":60,"completionDate":"2021-12-01"},{"nctId":"NCT02338921","phase":"PHASE4","title":"Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2015-01","conditions":["Type 2 Diabetes"],"enrollment":78,"completionDate":"2021-12-31"},{"nctId":"NCT02609815","phase":"NA","title":"Initial Combination of Gemigliptin and Metformin on Microbiota Change","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2015-11-01","conditions":["Diabetes"],"enrollment":70,"completionDate":"2021-03-15"},{"nctId":"NCT02956044","phase":"PHASE1","title":"Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin","status":"COMPLETED","sponsor":"Theracos","startDate":"2016-11","conditions":["Type2 Diabetes Mellitus"],"enrollment":54,"completionDate":"2017-03"},{"nctId":"NCT02649465","phase":"PHASE4","title":"SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD","status":"COMPLETED","sponsor":"Kanazawa University","startDate":"2015-11-11","conditions":["Non-alcoholic Fatty Liver Disease"],"enrollment":40,"completionDate":"2021-06-30"},{"nctId":"NCT02769481","phase":"PHASE3","title":"Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects","status":"COMPLETED","sponsor":"Theracos","startDate":"2016-08-15","conditions":["Type 2 Diabetes Mellitus"],"enrollment":426,"completionDate":"2019-06-14"},{"nctId":"NCT03332771","phase":"PHASE3","title":"Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2017-12-01","conditions":["Type 2 Diabetes Mellitus"],"enrollment":954,"completionDate":"2019-09-06"},{"nctId":"NCT01437813","phase":"PHASE1","title":"BIOAVAILABILITY OF Glimepiride/Extended Release Metformin (GLI/METXR): High Fat Diet Study","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2011-01","conditions":["Healthy"],"enrollment":24,"completionDate":"2011-03"},{"nctId":"NCT01437800","phase":"PHASE1","title":"BIOAVAILABILITY OF GLI/METXR (4/850 mg)","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2011-01","conditions":["Healthy"],"enrollment":24,"completionDate":"2011-03"},{"nctId":"NCT00679237","phase":"NA","title":"Risk Reduction in Coronary Heart Disease","status":"COMPLETED","sponsor":"Sorlandet Hospital HF","startDate":"2007-09","conditions":["Coronary Heart Disease"],"enrollment":1600,"completionDate":"2019-12"},{"nctId":"NCT00106340","phase":"PHASE3","title":"Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-03","conditions":["Diabetes Mellitus, Type 2"],"enrollment":3118,"completionDate":"2008-05-20"},{"nctId":"NCT04470310","phase":"PHASE4","title":"Glimepiride, Alogliptin and Alogliptin+Pioglitazone Combination","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2015-12-31","conditions":["Type 2 Diabetes Mellitus"],"enrollment":99,"completionDate":"2021-08-31"},{"nctId":"NCT02973477","phase":"PHASE4","title":"Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2017-01-12","conditions":["Type2 Diabetes","Cardiovascular Diseases"],"enrollment":45,"completionDate":"2019-08-22"},{"nctId":"NCT03648424","phase":"","title":"Prediction of Findings From the Ongoing CAROLINA Trial Using Healthcare Database Analyses","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2011-05-01","conditions":["Type 2 Diabetes Mellitus"],"enrollment":48262,"completionDate":"2019-06-01"},{"nctId":"NCT02395237","phase":"PHASE1","title":"COMPOUND (INN): HOE490O - GLIMEPIRIDE / METFORMIN HCl (Amaryl® M)0 (Glimepiride/Metformin Hydrochloride Immediate Release Combination Tablet) in Fed Conditions in Healthy Male and/or Female Subjects.","status":"WITHDRAWN","sponsor":"Pharmaceutical Research Unit, Jordan","startDate":"2015-05","conditions":["Healthy"],"enrollment":0,"completionDate":"2015-12"},{"nctId":"NCT02964572","phase":"NA","title":"Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2016-11","conditions":["Type2 Diabetes Mellitus"],"enrollment":61,"completionDate":"2017-07"},{"nctId":"NCT02419612","phase":"PHASE3","title":"A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-08-14","conditions":["Diabetes"],"enrollment":444,"completionDate":"2019-09-18"},{"nctId":"NCT04287387","phase":"PHASE4","title":"Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic Agents","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-03-02","conditions":["Type2 Diabetes Mellitus"],"enrollment":180,"completionDate":"2021-03-02"},{"nctId":"NCT04237493","phase":"PHASE4","title":"Dosage Reduction and Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramadan","status":"COMPLETED","sponsor":"University of Jordan","startDate":"2017-02-14","conditions":["Diabetes Mellitus, Type 2"],"enrollment":687,"completionDate":"2017-07-24"},{"nctId":"NCT03804411","phase":"PHASE4","title":"Prognostic Predictors of Response to Hypoglycemic Therapy","status":"UNKNOWN","sponsor":"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health","startDate":"2017-08-01","conditions":["Diabetes Mellitus, Type 2"],"enrollment":800,"completionDate":"2020-05"},{"nctId":"NCT02694263","phase":"PHASE4","title":"Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan","status":"COMPLETED","sponsor":"University of Leicester","startDate":"2016-07","conditions":["Diabetes Mellitus, Type 2"],"enrollment":25,"completionDate":"2018-09-13"},{"nctId":"NCT01243424","phase":"PHASE3","title":"CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-11-11","conditions":["Diabetes Mellitus, Type 2"],"enrollment":6103,"completionDate":"2018-08-21"},{"nctId":"NCT02072096","phase":"PHASE4","title":"A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2014-02","conditions":["Diabetes Mellitus, Type 2"],"enrollment":192,"completionDate":"2015-10"},{"nctId":"NCT01644500","phase":"PHASE3","title":"A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-07","conditions":["Type 2 Diabetes Mellitus"],"enrollment":737,"completionDate":"2014-08"},{"nctId":"NCT02564926","phase":"PHASE4","title":"Foxiga Korea Local Phase 4 Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-01-05","conditions":["Diabetes Mellitus, Type 2"],"enrollment":125,"completionDate":"2018-01-15"},{"nctId":"NCT02312063","phase":"PHASE4","title":"Dietary Impacts on Glucose-lowering Effects of Sitagliptin in Type 2 Diabetes","status":"COMPLETED","sponsor":"Kansai Electric Power Hospital","startDate":"2015-02","conditions":["Diabetes Mellitus, Type 2"],"enrollment":48,"completionDate":"2016-05"},{"nctId":"NCT03081676","phase":"NA","title":"The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea","status":"COMPLETED","sponsor":"University Hospital, Gentofte, Copenhagen","startDate":"2017-03-08","conditions":["Maturity-Onset Diabetes of the Young, Type 3"],"enrollment":20,"completionDate":"2018-06-01"},{"nctId":"NCT03983551","phase":"PHASE4","title":"Comparing the Renal Effect of Dipeptidyl-peptidase 4 Inhibitors and Sulfonylureas","status":"COMPLETED","sponsor":"Changhua Christian Hospital","startDate":"2016-03-01","conditions":["Type 2 Diabetes Mellitus","Proteinuria"],"enrollment":101,"completionDate":"2018-02-28"},{"nctId":"NCT01999218","phase":"PHASE3","title":"Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-12-16","conditions":["Type 2 Diabetes Mellitus"],"enrollment":1326,"completionDate":"2017-04-18"},{"nctId":"NCT02471404","phase":"PHASE4","title":"Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-09-21","conditions":["Type 2 Diabetes Mellitus","Inadequate Glycaemic Control"],"enrollment":939,"completionDate":"2017-03-13"},{"nctId":"NCT02728453","phase":"PHASE4","title":"SGLT2 Inhibition and Left Ventricular Mass","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2016-04-27","conditions":["Diabetes Mellitus Type 2"],"enrollment":7,"completionDate":"2017-09-27"},{"nctId":"NCT02188186","phase":"PHASE4","title":"Therapeutic Efficacy of Triple Combination in Drug-naïve Korean Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2014-07","conditions":["Type 2 Diabetes"],"enrollment":200,"completionDate":"2018-09"},{"nctId":"NCT03060980","phase":"PHASE3","title":"Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin","status":"TERMINATED","sponsor":"Intarcia Therapeutics","startDate":"2017-03-03","conditions":["Diabetes Mellitus, Type 2"],"enrollment":245,"completionDate":"2018-01-26"},{"nctId":"NCT02373865","phase":"PHASE4","title":"Risk of Nocturnal Hypoglycemia and Arrhythmias With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes","status":"TERMINATED","sponsor":"GWT-TUD GmbH","startDate":"2015-09","conditions":["Diabetes Mellitus Type 2"],"enrollment":4,"completionDate":"2017-01"},{"nctId":"NCT02630706","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-12-16","conditions":["Type 2 Diabetes Mellitus"],"enrollment":506,"completionDate":"2017-12-27"},{"nctId":"NCT02985242","phase":"PHASE4","title":"Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2017-06-12","conditions":["Diabetes Mellitus, Type II"],"enrollment":6,"completionDate":"2018-08-16"},{"nctId":"NCT01404676","phase":"PHASE4","title":"The Effect of Vildagliptin Based Treatment Versus Sulfonylurea on Glycemic Variability, Oxidative Stress, GLP-1, and Endothelial Function in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2010-06","conditions":["Type 2 Diabetes Mellitus"],"enrollment":34,"completionDate":"2012-05"},{"nctId":"NCT02226003","phase":"PHASE3","title":"Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-09-23","conditions":["Type 2 Diabetes Mellitus"],"enrollment":291,"completionDate":"2016-02-23"},{"nctId":"NCT02036515","phase":"PHASE3","title":"Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-03-12","conditions":["Type 2 Diabetes Mellitus"],"enrollment":464,"completionDate":"2016-06-06"},{"nctId":"NCT02099110","phase":"PHASE3","title":"Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-04-22","conditions":["Type 2 Diabetes Mellitus"],"enrollment":1233,"completionDate":"2016-05-26"},{"nctId":"NCT01704261","phase":"PHASE3","title":"Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-18","conditions":["Type 2 Diabetes Mellitus"],"enrollment":307,"completionDate":"2014-12-23"},{"nctId":"NCT01841697","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-06-13","conditions":["Type 2 Diabetes"],"enrollment":642,"completionDate":"2014-11-17"},{"nctId":"NCT01755156","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-01-11","conditions":["Type 2 Diabetes Mellitus"],"enrollment":402,"completionDate":"2016-03-16"},{"nctId":"NCT01697592","phase":"PHASE3","title":"Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-24","conditions":["Type 2 Diabetes Mellitus"],"enrollment":585,"completionDate":"2014-05-08"},{"nctId":"NCT01717313","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-05","conditions":["Type 2 Diabetes Mellitus"],"enrollment":329,"completionDate":"2015-06-19"},{"nctId":"NCT01863667","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate (MK-3102-027)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-07-08","conditions":["Type 2 Diabetes Mellitus"],"enrollment":65,"completionDate":"2014-04-03"},{"nctId":"NCT02033889","phase":"PHASE3","title":"A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-12-13","conditions":["Type 2 Diabetes Mellitus"],"enrollment":621,"completionDate":"2017-08-03"},{"nctId":"NCT01682759","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-09-10","conditions":["Type 2 Diabetes Mellitus"],"enrollment":751,"completionDate":"2015-01-26"},{"nctId":"NCT00427154","phase":"PHASE3","title":"Effect of Inhaled Pre-prandial Human Insulin on Blood Glucose Control in Type 2 Diabetes","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2007-01-10","conditions":["Diabetes","Diabetes Mellitus, Type 2"],"enrollment":227,"completionDate":"2008-03-11"},{"nctId":"NCT01678820","phase":"PHASE3","title":"A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-10","conditions":["Type 2 Diabetes Mellitus"],"enrollment":299,"completionDate":"2013-11-01"},{"nctId":"NCT00993187","phase":"PHASE4","title":"Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-05-04","conditions":["Type 2 Diabetes Mellitus"],"enrollment":292,"completionDate":"2013-10-29"},{"nctId":"NCT01709305","phase":"PHASE4","title":"A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-11-08","conditions":["Type 2 Diabetes Mellitus"],"enrollment":5570,"completionDate":"2015-04-17"},{"nctId":"NCT01590771","phase":"PHASE3","title":"A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-07-09","conditions":["Type 2 Diabetes Mellitus"],"enrollment":498,"completionDate":"2014-06-24"},{"nctId":"NCT01614769","phase":"PHASE1","title":"Effects of Glimepiride on Recovery From Hypoglycemia in Participants With Type 2 Diabetes Mellitus (MK-0000-253)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-07-18","conditions":["Type 2 Diabetes Mellitus"],"enrollment":10,"completionDate":"2013-01-23"},{"nctId":"NCT01177384","phase":"PHASE3","title":"Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-01-25","conditions":["Type 2 Diabetes Mellitus"],"enrollment":380,"completionDate":"2013-03-25"},{"nctId":"NCT01477853","phase":"PHASE3","title":"A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-10-24","conditions":["Type 2 Diabetes Mellitus"],"enrollment":166,"completionDate":"2012-12-04"},{"nctId":"NCT02280486","phase":"PHASE4","title":"Efficacy and Safety of Saxagliptin VS. Glimepiride in Chinese T2DM Patients Controlled Inadequately With Metformin","status":"COMPLETED","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2015-01","conditions":["Type 2 Diabetes"],"enrollment":388,"completionDate":"2017-10"},{"nctId":"NCT03585777","phase":"","title":"Compare Serum Klotho Levels in Patients on Oral Antidiabetic Treatment","status":"UNKNOWN","sponsor":"Fayoum University","startDate":"2018-10-11","conditions":["Compare Serum Level of Klotho in Patients on Oral Antidiabetic Treatment"],"enrollment":90,"completionDate":"2019-03"},{"nctId":"NCT02567994","phase":"PHASE3","title":"Tenelia Triple Combination Study","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2015-04","conditions":["Type 2 Diabetes Mellitus"],"enrollment":201,"completionDate":"2017-12"},{"nctId":"NCT03009513","phase":"PHASE1","title":"Teneligliptin-Glimepiride DDI Study","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2017-01","conditions":["Diabetes Mellitus"],"enrollment":26,"completionDate":"2017-06"},{"nctId":"NCT01561976","phase":"NA","title":"Evaluation of Food Effect on the Pharmacokinetics of Sustained Release Metformin in Healthy Indian Volunteers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-01-30","conditions":["Diabetes Mellitus, Type 2"],"enrollment":30,"completionDate":"2012-02-21"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Tablet","formulations":[{"form":"TABLET","route":"ORAL","productName":"GLIMEPIRIDE"},{"form":"TABLET","route":"ORAL","productName":"Glimepiride"},{"form":"TABLET","route":"ORAL","productName":"Pioglitazone hydrochloride and glimepiride"},{"form":"TABLET","route":"ORAL","productName":"AMARYL"},{"form":"TABLET","route":"ORAL","productName":"Duetact"},{"form":"TABLET","route":"ORAL","productName":"pioglitazone and glimepiride"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000148425","MMSL":"4782","NDDF":"005624","UNII":"6KY687524K","VUID":"4020945","CHEBI":"CHEBI:5383","VANDF":"4020945","INN_ID":"5718","RXNORM":"25789","UMLSCUI":"C0061323","chemblId":"CHEMBL1481","ChEMBL_ID":"CHEMBL1481","KEGG_DRUG":"D00593","DRUGBANK_ID":"DB00222","PDB_CHEM_ID":" GMR","PUBCHEM_CID":"3476","SNOMEDCT_US":"109079009","IUPHAR_LIGAND_ID":"6820","MESH_SUPPLEMENTAL_RECORD_UI":"C057619"},"formularyStatus":[],"originalProduct":{"form":"TABLET","route":"ORAL","company":"Sanofi-Aventis U.S. LLC","brandName":"AMARYL","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1995-","companyName":"Sanofi","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"10.0 hours","clearance":"0.5 mL/min/kg","bioavailability":"99%","fractionUnbound":"0.005%","volumeOfDistribution":"0.19 L/kg"},"publicationCount":1742,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"A10BB12","allCodes":["A10BB12","A10BD04","A10BD06"]},"biosimilarFilings":[],"originalDeveloper":"Sanofi Aventis Us","recentPublications":[{"date":"2026 Mar 11","pmid":"41900041","title":"Applications of Carbon Dots and Graphene Quantum Dots in Treatment of Diabetes.","journal":"Molecules (Basel, Switzerland)"},{"date":"2026 Mar 26","pmid":"41888123","title":"Lactylation at lysine 145 fosters KAT8-TIP60 complex formation to promote p53 acetylation at lysine 120 and its pro-apoptotic function.","journal":"Nature communications"},{"date":"2026","pmid":"41884285","title":"Recent Advances in Glimepiride Solubility Improvement: A Focus on Formulation Technologies - A Narrative Review.","journal":"International journal of nanomedicine"},{"date":"2026","pmid":"41880439","title":"Cardioprotective effects of the ranolazine in myocardial infarction mediated by stimulation of the endogenous mediators involved in ischemic preconditioning.","journal":"Acta cirurgica brasileira"},{"date":"2026 Mar 16","pmid":"41840294","title":"Floating-Mucoadhesive Gastro-Retentive Tablets for Enhanced Oral Delivery of Glimepiride: Formulation, Optimization, and Controlled Release.","journal":"AAPS PharmSciTech"}],"combinationProducts":[{"brandName":"Duetact","ingredients":"glimepiride + pioglitazone"}],"companionDiagnostics":[],"genericManufacturers":17,"_genericFilersChecked":true,"genericManufacturerList":["Accord Hlthcare","Actavis Labs Fl Inc","Aurobindo Pharma Ltd","Carlsbad","Chartwell Molecular","Dr Reddys Labs Ltd","Epic Pharma Llc","Hikma Pharms","Micro Labs","Mylan","Prinston Inc","Quagen","Ranbaxy","Ranbaxy Labs Ltd","Regcon Holdings","Senores Pharms","Watson Labs"],"status":"approved","companyName":"Sanofi Aventis Us","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"1995","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1995-11-30T00:00:00.000Z","mah":"SANOFI AVENTIS US","brand_name_local":null,"application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1995-11-30T00:00:00.000Z","mah":"SANOFI AVENTIS US","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1995-11-30T00:00:00.000Z","mah":"SANOFI AVENTIS US","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1995-11-30T00:00:00.000Z","mah":"SANOFI AVENTIS US","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1995-11-30T00:00:00.000Z","mah":"SANOFI AVENTIS US","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1995-11-30T00:00:00.000Z","mah":"SANOFI AVENTIS US","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2012-05-31T00:00:00.000Z","mah":"PRINSTON INC","brand_name_local":null,"application_number":"ANDA077370"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2014-08-01T00:00:00.000Z","mah":"ACCORD HLTHCARE","brand_name_local":null,"application_number":"ANDA078181"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2015-06-30T00:00:00.000Z","mah":"CARLSBAD","brand_name_local":null,"application_number":"ANDA077911"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2017-12-27T00:00:00.000Z","mah":"AUROBINDO PHARMA LTD","brand_name_local":null,"application_number":"ANDA202759"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-11-26T00:00:00.000Z","mah":"REGCON HOLDINGS","brand_name_local":null,"application_number":"ANDA202112"},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:34:03.673197+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}